March 2025 observed high-water mark 01
3580 USD M [CV004] Diligence report
DispatchHealth
Full Diligence Report — August 2026
DispatchHealth has credible strategic relevance and enterprise proof in a hard-to-replicate care-at-home niche, but open evidence does not support paying a peak private-market mark without audited operating data and explicit reconciliation of the 2026 financing signal.
Cover facts
Company profile
DispatchHealth is a Denver-founded in-home acute-care company established in 2013 by Mark Prather and Kevin Riddleberger. The company built its business around dispatching advanced-practice clinicians and support teams into patients' homes to treat episodes that might otherwise drive emergency-department or inpatient utilization. After closing its Medically Home merger in June 2025, DispatchHealth positioned itself less as a house-call brand and more as a scaled health-system enablement platform spanning ER-alternative care, hospital-alternative care, transitional care, and CESIA workflow software. Public scale proof is meaningful—50+ enterprise customers, 1.2M+ patients treated, and 20+ states—but valuation and financing signals remain unusually noisy.
- Website
- www.dispatchhealth.com
- Founded
- 2013-01-01
- Founders
- Mark Prather, Kevin Riddleberger, Jennifer Webster
- Founding location
- Denver, Colorado, United States
- Headquarters
- Denver, Colorado, United States
- Product
- ER-alternative care at home, hospital-at-home / hospital-alternative care, transitional care, and CESIA-powered orchestration for complex care in the home.
- Customers
- Health systems, payers, risk-bearing providers, and enterprise care partners, with patients as end users rather than the only economic buyer.
- Business model
- Insurance-reimbursed and enterprise-partnered healthcare delivery: fee-for-service and value-based reimbursement across Medicare, Medicaid, and commercial channels, combined with health-system and payer partnership programs.
- Stage
- Late-stage private company following the 2025 Medically Home merger
- Funding status
- Public financing signals indicate major 2022, 2025, and 2026 private financings, but accessible valuation and total-funding figures conflict across alternative-data providers and are not reconcilable without cap-table documents.
Executive summary
Top strengths
- Strategic position in a difficult-to-replicate category that combines logistics, clinical operations, and payer/provider embedment.
- Meaningful public scale proof after the Medically Home merger, including 50+ enterprise customers, 1.2M+ patients treated, and 20+ states.
- Clear enterprise relevance to health systems and payers rather than a purely consumer-demand story.
- Potential strategic-buyer appeal for large healthcare platforms that want national in-home acute-care capabilities.
Top risks
- Valuation opacity: observable private-market marks range from roughly $703.5M to $3.58B, with no public cap-table explanation.
- Disclosure opacity: no audited public revenue, margin, EBITDA, or cash-flow denominator supports current pricing.
- Operational heaviness: field staffing, logistics, escalation, and market density matter more than in software businesses.
- Post-merger stress and competitor churn indicate the category is strategically relevant but not easy to monetize cleanly.
Open gaps
- Audited 2025 financials and 2026 YTD bridge.
- Full 2025 and 2026 financing documents, preference stack, and cap-table mechanics.
- Market-level unit economics and mature-market contribution margins.
- Customer concentration, renewal, and retention data.
- Clinical incident, escalation, and service-level trend data.
Contents
01Company Overview
1.1 Identity, founding, and service model
DispatchHealth started in Denver in 2013 as a high-acuity house-call model built by emergency-care insiders who believed a large share of emergency and post-acute demand could be treated safely outside the hospital. The early company history matters because the model was never a light telehealth front end. Alta Partners, AAPA, and Becker’s all describe a business built around dispatching clinician teams into the home, using logistics and technology to recreate important emergency-department and hospital workflows at lower cost and with less friction. That origin still shows up in the current product definition, but the company’s language has become more enterprise-oriented. Official 2025-2026 materials now frame DispatchHealth as a complex-care-at-home platform with three core lines—ER-alternative care, hospital-alternative care, and transitional care—plus CESIA workflow software, specialty networks, mobile imaging, and mobile lab support. The result is a company that sits between direct provider, outsourced operating partner, and care-enablement infrastructure vendor. That broader identity gives later chapters room to analyze DispatchHealth not only as a care-delivery brand but as a health-system infrastructure layer.[CO001, CO002, CO003, CO004, CO009, CO010]
| Metric | Value / status | Date | Confidence | Gap / caveat |
|---|---|---|---|---|
| Founding year | 2013 | 2013 | High | Corroborated by Alta, AAPA, and Becker’s. |
| HQ | Denver, Colorado | 2026 | Medium | Public profile and bios agree, but no detailed corporate-entity filing was reviewed. |
| Enterprise customers | 50+ | 2025-06 | Medium | Company-claimed merger-close figure. |
| Geographic footprint | 20+ states; 50 metro areas around merger announcement | 2025-03 to 2025-06 | Medium | States and metro counts come from different company disclosures. |
| Patients treated since inception | 1.2M+ | 2025-06 | Medium | Company-claimed cumulative count. |
| ER avoidance | 58% | 2025-06 | Medium | Repeated company statistic, not independently audited. |
| 30-day readmission rate | 8.5% | 2025-06 | Medium | Repeated company statistic, plus supportive study framing. |
| Patient satisfaction | 98% | 2025-06 | Medium | Company metric; separate NPS evidence comes from the 2023 study. |
| Total capital raised | > $700M publicly referenced; exact current total disputed | 2025-09 | Low | Open sources conflict with alternative-data providers. |
| Current valuation | Not cleanly corroborated from accessible open sources | 2026-08-20 | Low | Alternative-data pages point higher than older public financing anchors. |
Rows mix well-supported cumulative operating metrics with clearly flagged gaps on private financing and valuation.
[CO001, CO013, CO015, CO016, CO024, CO027]How founders, service lines, and CESIA connect to the current enterprise value proposition.
Flow is qualitative and shows the commercial architecture rather than system code paths.
[CO001, CO002, CO009, CO010, CO011, CO012]1.2 Leadership transition and post-merger governance
Leadership continuity exists, but it is no longer a simple founder-CEO story. Mark Prather remains a critical figure as co-founder and executive chair, and his public comments still anchor strategic messaging around the merger and the clinical case for care at home. However, operating authority has clearly shifted to Jennifer Webster, who is now the chief executive and public face of the combined company. That shift matters because DispatchHealth is no longer just proving a care concept; it is integrating a large merger, resegmenting its go-to-market model, and trying to become an operating partner to health systems at scale. The next layer of governance is the post-merger bench. Erin Bartley moved from Medically Home’s COO seat into senior transformation and then president duties at DispatchHealth, while Bill Kramer, David Wilkinson, and Pippa Shulman round out a bench that blends legal, finance, operational, and clinical continuity. Public board detail is still thin, so the main diligence read is not board sophistication but management concentration: Webster, Bartley, Shulman, and Prather are the core human nodes that later chapters repeatedly depend on.[CO005, CO006, CO007, CO008, CO032, CO033]
| Person | Role | Background | Functional coverage / continuity | Key-person dependency |
|---|---|---|---|---|
| Mark Prather | Co-founder; executive chair | Emergency physician and original architect of the house-call care model | Clinical vision, merger narrative, founder continuity | High — strategic continuity still runs through him |
| Kevin Riddleberger | Co-founder; former chief strategy voice | PA and healthcare operator focused on cost and access reform | Founding logic, EMS-to-home model, growth narrative | Medium — less central to daily public operations in 2026 |
| Jennifer Webster | Chief executive officer | Large-company and PE-backed healthcare operator brought in during 2023 | Operating discipline, post-merger integration, B2B positioning | Critical — current execution anchor |
| Erin Bartley | President | Former Medically Home COO with market-expansion and integration experience | Operations, growth, and transformation during complex-care scale-up | High — key to merger execution |
| Pippa Shulman | Chief medical officer | Clinical executive active in hospital-at-home strategy and outcomes messaging | Clinical quality, physician credibility, customer trust | High — links product claims to care standards |
Table focuses on the bench that materially shapes care-model execution and integration rather than attempting a full org chart.
[CO001, CO002, CO005, CO006, CO007, CO008]| Stakeholder | Role | Control or economic importance | Why it matters | Diligence ask |
|---|---|---|---|---|
| Health systems | Core enterprise buyers and clinical partners | Drive branded program deployment and volume | Validate whether DispatchHealth is an infrastructure partner rather than only a visit-based provider | Request renewal, utilization, and economics by health-system cohort |
| Payers and MA / Medicaid plans | Channel and reimbursement partners | Influence patient flow and reimbursement terms | Essential to margin quality and coverage breadth | Request payer mix and value-based contract economics |
| Optum Ventures / Humana / other named investors | Capital providers and strategic backers | Signal category support and healthcare-industry connectivity | May affect commercial access and future financing options | Request current cap table and board / observer rights |
| Medically Home legacy team | Technology, command-center, and hospital-at-home asset base | Their integration determines whether the merger creates real leverage | Execution risk sits here as much as synergy opportunity | Request post-merger product and workforce integration milestones |
| Jennifer Webster / operating bench | Execution leadership | Decision concentration over integration, portfolio focus, and customer strategy | Human capital concentration is material to the thesis | Review succession plans and retention packages |
Investor and stakeholder visibility is good at a narrative level but weak on current cap-table precision.
[CO005, CO006, CO007, CO008, CO013, CO014]1.3 Scale proof, financing history, and buyer traction
The best-supported scale facts come from merger documents and partner announcements rather than audited financial disclosures. DispatchHealth said at merger close that it had treated more than 1.2 million people, worked in more than 20 states, and supported more than 50 enterprise customers. It also repeated operating outcome statistics—58% ER avoidance, 8.5% 30-day readmissions, 98% satisfaction, and roughly $1.5 billion in medical savings—that appeared across official releases and the 2023 outcomes study. Even if some of those numbers are management-selected, they are directionally corroborated by the company’s repeated use of hospital-alternative and transitional-care workflows with named partners. Funding history is less clean. Fierce documented a $135.8 million Series C in 2020 led by Optum Ventures, while a later Medhealth Outlook write-up described a 2022 $259 million Series E plus debt financing. Home Health Care News later summarized total capital raised at more than $700 million. What remains weak is the current 2025 valuation story: alternative-data pages point to a $160 million round and a far higher valuation, but the accessible open-source record does not corroborate the number with the same confidence as the older rounds.[CO013, CO014, CO015, CO016, CO019, CO020]
| Date | Event | Type | Amount / status | Participants | Implication |
|---|---|---|---|---|---|
| 2013 | DispatchHealth founded in Denver | founding | Company formed | Mark Prather; Kevin Riddleberger | Starts the home-based acute-care platform |
| 2015-10-05 | Becker’s profiles the company as DispatchHealth after the True North Health Navigation phase | governance | Seed-funded startup | Kevin Riddleberger; Becker’s | Shows early rebrand and consumer-home-visit positioning |
| 2020-12 | Series C reported by Fierce | financing | $135.8M | Optum Ventures; Humana; Oak HC/FT; others | Adds strategic capital and market credibility |
| 2022-11 | Series E plus debt described by Medhealth Outlook | financing | $259M equity plus debt commitments | Optum Ventures; Humana; Blue Shield of California; K2; SVB | Funds expansion and platform development |
| 2024-11 | ACHC in-home hospital accreditation | regulatory | First-ever accreditation claimed | ACHC; DispatchHealth | Quality marker for hospital-at-home credibility |
| 2025-03-18 | DispatchHealth and Medically Home announce merger | partnership | Terms undisclosed | DispatchHealth; Medically Home | Creates national hospital-at-home platform ambition |
| 2025-06-04 | Merger closes under DispatchHealth brand | governance | Combined company operational | DispatchHealth; Medically Home | Moves from strategy to integration phase |
| 2025-09 | Markets cut back and layoffs reported | adverse | One market exit; nine service scale-backs | DispatchHealth; Home Health Care News | Shows post-merger portfolio rationalization |
| 2026-02 | Saint Francis hospital-at-home launch | partnership | New regional program | DispatchHealth; Saint Francis | Shows expansion can still occur after retrenchment |
| 2026-07-31 | Refined B2B market focus announced | product | Website and positioning reset | DispatchHealth | Confirms enablement-first strategy |
Chronology mixes founding, financing, product, partnership, quality, and adverse events that shape later diligence chapters.
[CO001, CO003, CO004, CO013, CO014, CO019]Key inflection points from founding through merger integration and the 2026 strategy reset.
[CO001, CO003, CO004, CO013, CO014, CO019]1.4 Current status, documentation gaps, and adverse signals
The central diligence tension is that DispatchHealth has strong operating proof but messy public denominators. The company is clearly active in 2026: it is shipping a sharper B2B story, integrating Medically Home, promoting senior operators, and launching hospital-at-home partnerships like Saint Francis. Yet public headcount sources now diverge sharply. Healthcare Dive cited more than 2,200 employees at merger close, LeadIQ places the company in a 501-1,000 range, Unify’s visible departmental totals imply a workforce closer to the high hundreds, and Glassdoor’s archived profile still shows a much broader 1,001-5,000 range. That is enough to prove restructuring, not enough to publish a clean people count. The clearest adverse file is the September 2025 scale-back. Home Health Care News reported one market exit, service retrenchment in nine others, and layoffs only months after merger close. That does not negate the strategic logic of the combined platform, but it does mean DispatchHealth should be treated as a company still rationalizing its footprint rather than one on a smooth linear expansion path. Public review surfaces and broken review pages add small but real documentation noise around customer and employee sentiment.[CO028, CO031, CO032, CO033, CO034, CO035]
Compact view of scale, proof, and public-information quality.
This figure mixes hard counts with qualitative diligence scores to capture what the public record supports today.
[CO015, CO016, CO027, CO028, CO029, CO030]02Market Analysis
2.1 Market boundary: complex care at home, not generic virtual care
DispatchHealth should be analyzed inside a broader complex-care-at-home market rather than inside consumer telehealth or conventional home health. The company’s own post-merger language makes this explicit. Its offering now spans ER-alternative visits, inpatient hospital-level care at home, and transitional recovery services, each of which substitutes for a different piece of brick-and-mortar utilization. That means the true economic comparison set is not “video visit versus office visit.” It is emergency department versus home-based acute intervention, inpatient admission versus hospital-at-home episode, and skilled nursing or unmanaged discharge versus coordinated recovery at home. That distinction matters for sizing. The category is closer to hospital operations, payer medical-loss management, and post-acute utilization control than to consumer app growth. Buyers care about bed capacity, readmissions, episode cost, and clinical confidence. Substitute pathways remain the emergency department, inpatient unit, skilled nursing facility, and fragmented home services. Amazon One Medical and similar virtual-care products are still relevant as adjacent comparison points, but they sit materially lower in acuity and operational complexity than DispatchHealth’s target use cases.[CM001, CM002, CM003, CM004, CM020, CM031]
| Segment / category | Included spend | Excluded spend | Buyer / payer | Relevance |
|---|---|---|---|---|
| ER-alternative acute care | Serious but non-life-threatening episodes that can avoid an ED visit | Routine tele-triage and low-acuity retail urgent care | Health systems, MA plans, employer or risk-bearing contracts | Direct fit with DispatchHealth legacy mobile model |
| Hospital-at-home / inpatient alternative | Inpatient-level acute episodes shifted to the home under waiver or contract | Traditional home health without acute escalation | Hospitals, health systems, some payers | Direct fit with Medically Home integration and hospital programs |
| Transitional recovery / readmission avoidance | Post-discharge, ER-follow-up, and high-risk recovery episodes | Long-tail custodial home services | Health systems, payers, value-based entities | Direct fit with DispatchHealth transitional care |
| Consumer primary-care subscription | Membership primary care and low-acuity virtual access | High-acuity field care and command-center logistics | Individual consumers and employers | Adjacent comparison only; not the core market |
| Post-acute coordination platforms | SNF optimization, discharge orchestration, home-benefit management | Owned high-acuity bedside clinical delivery | Payers and discharge-management teams | Important adjacent competitor layer rather than full substitute |
Table separates the acute-complex category from lower-acuity or purely administrative adjacencies.
[CM001, CM002, CM003, CM004, CM020, CM031]2.2 Policy and reimbursement structure shape the category
Hospital-at-home growth still depends heavily on policy architecture. CMS launched the Acute Hospital Care at Home initiative during the pandemic and Congress has now extended it through September 2030, which removes the most immediate existential policy risk for participating hospitals. The AHCAH structure matters because it effectively legitimizes inpatient-level care in the home by allowing hospitals to preserve inpatient reimbursement while meeting specific safety and staffing conditions. Public implementation resources emphasize two daily in-person visits, immediate remote access to care teams, and ongoing quality reporting. Even with the extension, the payment surface is uneven. CHCS documented strong Medicare participation, some Medicare Advantage adoption, and only limited Medicaid fee-for-service coverage across 12 states as of 2025. That makes the market real but still unevenly monetizable. For DispatchHealth specifically, this means part of the opportunity rides on federal waiver logic while another part rides on direct health-system and payer contracts for ER avoidance and transitional care. In other words, reimbursement is a layered stack, not a single national fee schedule.[CM005, CM006, CM007, CM008, CM009, CM010]
| Driver / constraint | Direction | Timing | Implication | Diligence ask |
|---|---|---|---|---|
| AHCAH waiver extended to 2030 | Positive | Near term | Reduces the largest policy cliff for hospital-at-home adoption | Track whether participating hospitals convert extensions into budget commitments |
| Aging population and preference for home-based care | Positive | Structural | Supports long-run demand for at-home acute and post-acute models | Request cohort mix by age and condition |
| Health-system bed pressure and labor scarcity | Positive | Current | Makes home-based substitution economically appealing | Review hospital partner capacity metrics and avoided bed days |
| Medicaid coverage remains limited to a minority of states | Negative | Current | Constrains universality and slows addressable reimbursement | Request state-by-state payer and Medicaid economics |
| Operational complexity in staffing, diagnostics, and logistics | Negative | Current | Raises barriers to entry but also slows deployment velocity | Request productivity and service-level metrics for field teams and command centers |
| Market-estimate inconsistency | Warning | Ongoing | Supports thesis direction but weakens precision for valuation work | Request internal sizing and pipeline segmentation used by management |
The market is attractive because of structural demand and policy progress, but reimbursement and operations still create real friction.
[CM005, CM008, CM009, CM025, CM026, CM027]Care-at-home adoption is gated by policy, staffing, technology, and workflow integration.
Indexed values are directional and describe friction in deployment rather than measured conversion rates.
[CM005, CM006, CM019, CM027, CM028, CM029]2.3 Sizing lenses are broad; demand drivers are real
Published market estimates point in the same directional direction but vary widely in magnitude. Mordor pegs the hospital-at-home market above $42 billion in 2026, Insight Partners uses a high-thirties baseline, and DispatchHealth’s own merger pitch referenced a far broader $300 billion figure from Chilmark. Investors should not average those numbers. They capture different geographies, service definitions, and time horizons. What they do show is that the category is already large enough to matter if care-at-home reimbursement, logistics, and staffing can hold. The stronger part of the market case is not the exact TAM number but the demand logic behind it. Aging populations, patient preference for home-based care, bed-capacity pressure, and readmission economics all favor the model. Peer-reviewed reviews add substance by showing lower costs, lower complications, and frequently better or comparable outcomes versus traditional hospitalization. Those facts support a positive category direction even if DispatchHealth’s own share of that category cannot yet be sized precisely from public information.[CM012, CM013, CM014, CM015, CM016, CM017]
| Publisher / lens | Year | Geography | Value | Methodology | Confidence | Limitation |
|---|---|---|---|---|---|---|
| Mordor Intelligence hospital-at-home market | 2026 | Global | $42.08B in 2026; $61.55B by 2031 | Analyst market forecast | Medium | Broad category definition and proprietary methodology |
| Insight Partners hospital-at-home market | 2025 | Global | $37.17B in 2025; $72.84B by 2034 | Analyst market forecast | Medium | Different scope and horizon from Mordor |
| DispatchHealth / Chilmark citation | 2025 | Implied U.S. / broad category | $300B by 2028 | Company-cited research from merger narrative | Low | Likely includes a much broader care-at-home universe |
| DispatchHealth-relevant SAM | 2026 | U.S. institutional buyers | Not publicly disclosed | Constrained subset: high-acuity, reimbursable, logistics-heavy episodes | Medium | Needs payer, acuity, and contract segmentation |
| DispatchHealth SOM | 2026 | U.S. served markets | Not publicly disclosed | Would require utilization, win-rate, and contract-density data | Low | Private company data absent |
Sizing rows intentionally mix published TAM lenses with analysis-driven SAM and SOM placeholders to preserve comparability limits.
[CM015, CM016, CM017, CM018, CM019, CM020]A broad hospital-at-home TAM narrows to a DispatchHealth-relevant SAM and an undisclosed SOM.
The pyramid mixes published TAM lenses with qualitative narrowing stages; only the outer layers have public numbers.
[CM015, CM016, CM017, CM018, CM019, CM020]Published market estimates span materially different scopes.
Single-point published estimates are shown as flat ranges to illustrate scope dispersion, not measurement certainty.
[CM015, CM016, CM017, CM018]2.4 Buyer map and adoption constraints define execution difficulty
The buyer map is unusually multi-sided. Health systems buy care-at-home to create capacity, keep patients within branded systems, and manage labor and throughput constraints. Payers and value-based entities buy it to reduce avoidable ER and inpatient spend. Patients and caregivers are the end users, but they are rarely the budget owners. That is why DispatchHealth’s 2026 strategy sharpened toward B2B enablement. The company wins when it fits into institutional workflows and reimbursement structures, not when it behaves like a stand-alone consumer app. The constraint side is equally important. The model requires staffing, mobile logistics, diagnostics, command-center tools, EMR integration, and payer alignment. Those demands create meaningful barriers to entry, but they also slow rollout and make the market patchier than the headline TAM suggests. Waiver uncertainty delayed some programs during 2025, and Medicaid adaptation remains limited. The practical implication is that category growth should continue, but investors should treat adoption as operationally staged rather than frictionless.[CM021, CM022, CM023, CM024, CM027, CM028]
| Segment | Buyer | User | Payer | Workflow | Budget owner | Adoption trigger |
|---|---|---|---|---|---|---|
| Hospital-at-home programs | Health systems / hospitals | Patients, bedside teams, command center | Medicare FFS, MA, health-system contracts | Inpatient alternative | Hospital operations / CFO / clinical leadership | Capacity relief and quality goals |
| ER-avoidance home episodes | Health plans, health systems, risk-bearing entities | Patients and mobile care teams | Payer contract or risk-bearing entity | Acute episode diversion | Medical management / network operations | Avoided ED utilization |
| Transitional care and readmission reduction | Health systems and payers | Discharged patients and caregivers | Health-system quality budget or payer medical management | Recovery support | Care management / population health | Readmission pressure |
| Medicaid-focused hospital-at-home | State agencies, Medicaid MCOs, hospitals | Dually eligible or high-need members | Medicaid FFS or MCO | Acute in-home episode with extra social supports | State / plan leadership | Targeted population management |
| Consumer virtual-first care | Individuals or employers | Low-acuity patients | Self-pay or employer / insurance | Membership or pay-per-visit | Consumer / benefits budget | Convenience rather than acute replacement |
Buyer, user, and payer roles split clearly in this market; the end user is rarely the budget owner.
[CM021, CM022, CM023, CM024, CM031, CM032]Institutional buyers dominate, while patients are the end users rather than the budget holders.
Cells summarize public workflow patterns rather than contract language from any single payer.
[CM021, CM022, CM023, CM024, CM027, CM031]03Competitors
3.1 Landscape: direct peers, adjacencies, and incumbents
DispatchHealth sits in a messy competitive field where the most important rivals do not all look alike. Some competitors are direct: companies that help a hospital or payer move acute care into the home. Others are adjacencies: primary-care memberships, remote-monitoring platforms, post-acute orchestration tools, or internal health-system programs that can absorb part of the same episode. The right comparison set therefore includes CareCentrix, Current Health, Amazon One Medical, Contessa’s legacy footprint, health-system internal build, and the legacy facility pathway itself. That framing matters because the core substitution is still brick-and-mortar utilization. Emergency departments, inpatient units, and skilled nursing pathways remain the default alternatives. The real competitive question is which vendor or operating model captures the right to redirect those episodes. DispatchHealth’s edge is that it bundles field delivery, logistics, and enterprise workflow. Its risk is that many components of the stack can be unbundled or built internally.[CP001, CP002, CP003, CP010, CP031, CP032]
| Competitor / alternative | Category | Scale / funding signal | Target customer | Differentiation | Limitation |
|---|---|---|---|---|---|
| DispatchHealth | Full-stack complex care at home | Merger-created national platform; 50+ enterprise customers claimed | Health systems, payers, risk-bearing entities | Field delivery + CESIA + hospital-at-home + transitional care | Enterprise pricing and renewal data remain private |
| CareCentrix | Post-acute coordination / site-of-care optimization | Large payer-facing home-benefit manager | Payers, discharge planners, health systems | Authorization, orchestration, post-acute steering | Public materials do not show a comparable bedside acute-delivery network |
| Amazon One Medical | Consumer primary care / telehealth adjacency | National consumer brand with Prime hooks | Consumers, employers, some enterprise buyers | Frictionless front door, explicit membership pricing | Lower acuity than hospital-alternative home care |
| Current Health | Hospital-at-home infrastructure / monitoring | 70,000+ patients cited; ownership changed in 2025 | Health systems | RPM and enabling tech for home-based programs | Not presented as a national dispatch clinician operator |
| Internal hospital build | Status-quo alternative | Supported by AHCAH policy architecture | Hospitals and health systems | Clinical control and embedded brand trust | Execution burden stays with the hospital |
| Contessa legacy footprint | Legacy hospital-at-home benchmark | Public site inactive in 2026 | Health systems | Historically relevant category proof point | Low current visibility as an active independent go-to-market rival |
Rows compare direct peers, adjacencies, and substitutes because buyers can assemble this category in multiple ways.
[CP001, CP003, CP004, CP005, CP007, CP008]Ordinal map of buyer-embedded clinical depth versus consumer/distribution reach.
X scores reflect high-acuity workflow depth; Y scores reflect public brand or distribution reach. Values are ordinal, not measured market share.
[CP002, CP003, CP005, CP007, CP010, CP012]3.2 Peer profiles show different forms of overlap
CareCentrix reads as a strong post-acute and site-of-care workflow competitor, but not as a mirror image of DispatchHealth’s bedside clinical model. Amazon One Medical has the opposite shape: exceptional consumer brand reach and explicit pricing, but a lower-acuity product set centered on primary care and telehealth. Current Health is more infrastructure-heavy still, with hospital-at-home enablement, monitoring, and health-system partnerships rather than a national mobile-clinician dispatch layer. Contessa’s inactive public site weakens its visibility as a live independent benchmark, though it remains a proof point that the category has seen consolidation and churn. Those differences mean buyers can choose between full-stack outsourced care, point solutions, or internal assembly. DispatchHealth’s post-merger scope is publicly broader than the adjacencies in this source set, especially after absorbing Medically Home’s hospital-at-home assets. But breadth alone does not decide every account; buyer preferences around reimbursement, control, and staffing can still shift deals to other models.[CP004, CP005, CP006, CP007, CP008, CP009]
| Capability | DispatchHealth | CareCentrix | Amazon One Medical | Current Health | Internal hospital build |
|---|---|---|---|---|---|
| High-acuity in-home episode delivery | Strong | Limited / not core public message | Weak | Weak | Variable by local program |
| Hospital-at-home infrastructure | Strong | Limited | Weak | Strong | Strong if resourced |
| Transitional / post-acute coordination | Strong | Strong | Weak | Moderate | Variable |
| Consumer acquisition brand | Moderate | Weak | Strong | Weak | Weak |
| Pricing transparency | Weak | Weak | Strong | Weak | Weak |
| EMR / workflow integration orientation | Strong | Moderate | Weak | Strong | Strong |
Strength labels are evidence-backed ordinal assessments from public materials, not customer-scored benchmarks.
[CP004, CP005, CP007, CP010, CP011, CP012]Capability matrix highlighting why the peer set overlaps unevenly rather than perfectly.
Labels summarize public capability signals and may understate private or custom deployments.
[CP004, CP005, CP007, CP010, CP011, CP013]3.3 Pricing opacity and embedded workflows shape competition
Public pricing is poor across the peer set. Amazon One Medical is the rare outlier with visible membership economics. DispatchHealth publishes patient affordability and insurance language, but not broad enterprise pricing. CareCentrix and Current Health also present capability narratives rather than rate cards. That means investors should assume deal economics are bespoke and negotiated, not standardized. It also makes public price competition hard to underwrite from outside. Where evidence is clearer is switching cost. Once a hospital or payer integrates staffing, EMR workflows, command-center processes, clinical protocols, and reimbursement handling into a care-at-home program, the vendor is harder to displace than a simple app subscription. Multi-homing is much easier for lower-acuity front-door products than for hospital-alternative delivery. In that sense, the category rewards operating reliability more than flashy top-of-funnel marketing. Procurement also tends to favor vendors that can shoulder implementation complexity quickly and reliably.[CP014, CP015, CP016, CP017, CP018, CP019]
| Provider | Public pricing visibility | Commercial model | Included capabilities | Unknowns | Implication |
|---|---|---|---|---|---|
| DispatchHealth | Partial | Insurance reimbursement plus enterprise contracts | Field care, diagnostics, logistics, transitional services | Episode pricing, guarantees, contract structure | Public diligence cannot benchmark price competitiveness cleanly |
| Amazon One Medical | High | Membership plus visit-based care surfaces | Primary care, telehealth, clinic access | Enterprise carve-outs and deeper partner economics | Most transparent public consumer comparator |
| CareCentrix | Low | Enterprise / payer contracting | Network management, post-acute orchestration | Case-rate structure and savings share | Likely negotiated on workflow and utilization value |
| Current Health | Low | Enterprise platform contracts | Monitoring and home-care enablement software | Device pricing, deployment fees, services scope | Hard to compare total cost with full-stack operators |
| Internal hospital build | Low | Capex + opex internal program cost | Branded home program inside health system | Productivity, staffing, and utilization assumptions | May look expensive upfront but preserve local control |
The absence of transparent enterprise rate cards is itself an important competitive finding.
[CP006, CP014, CP015, CP025, CP026, CP035]3.4 DispatchHealth has a real moat, but it is mostly operational
The most durable elements of DispatchHealth’s moat appear to be operational rather than purely technical. The company’s public file emphasizes clinical outcomes, ACHC accreditation, enterprise workflow software, and a logistics-heavy field model. That combination should be harder to copy than a lower-acuity digital benefit. It also suggests that health systems and payers may value a credible implementation partner more than a point feature. Still, the moat is not permanent. Internal hospital build remains credible, retailers could keep climbing up-acuity, and point-solution vendors can attack individual layers of the workflow. The market is also still structurally unsettled: Current Health changed hands again in 2025, Contessa’s public site went dark, and DispatchHealth itself scaled back in some markets after the merger. The competitive verdict is therefore favorable but conditional. DispatchHealth looks differentiated today, yet investors still need win-loss, renewal, and pricing proof before calling the moat durable. The category is fragmented enough that several models can coexist until operational winners separate more clearly.[CP020, CP021, CP022, CP023, CP024, CP033]
| Moat claim | Threat | Severity | Why it matters | Diligence ask |
|---|---|---|---|---|
| Operational logistics and staffing density are hard to copy | Internal build or regional operators can still recruit and replicate pieces | High | Execution moat is real but not exclusive | Request market-level productivity and launch-time benchmarks |
| CESIA and workflow integration embed the platform | Hospitals may prefer modular vendors or native EMR workflows | High | Integration can either lock in or be bypassed | Request renewal reasons and displacement cases |
| Outcomes and accreditation create trust | Competitors can accumulate their own safety data over time | Medium-High | Trust advantage decays if rivals prove equivalent quality | Request comparative RFP scorecards and customer references |
| Merged breadth improves account coverage | Breadth can also increase complexity and slow focus | Medium-High | A wide platform is valuable only if integrated well | Request post-merger product utilization by module |
| Category churn may eliminate rivals | Market churn can also create openings for fresh entrants | Medium | A turbulent market rewards speed and disciplined execution | Track new entrants and lost-deal reasons quarterly |
Severity reflects competitive underwriting impact rather than legal or patient-safety severity.
[CP016, CP017, CP018, CP020, CP021, CP022]Compact competitive-readiness view emphasizing what appears strongest and weakest in the public record.
KPI labels are underwriting summaries derived from the retained public evidence, not audited benchmarks.
[CP008, CP012, CP016, CP018, CP022, CP024]04Financials
4.1 Revenue model: institutional episodes, not lightweight subscription
DispatchHealth’s economic model is best read as a hybrid of reimbursed care episodes and enterprise contracting rather than as a conventional subscription software business. The company sells into expensive clinical workflows: ER avoidance, hospital-at-home, and transitional recovery. Those use cases can create revenue through claims reimbursement, payer agreements, health-system contracts, or a blend of all three depending on market and program design. The consumer-facing website supports this interpretation because it talks about insurance coverage and affordability, not about a broad consumer membership plan. The July 2026 strategy reset reinforces the same point. DispatchHealth now presents itself as a health-system enablement partner for complex care at home. That means go-to-market is institutional and solution oriented. It likely requires longer sales cycles and more deployment work than a standard digital-health app, but it also means revenue is attached to painful budget lines that hospitals and payers actively want to bend.[CI001, CI002, CI003, CI004, CI018, CI020]
| Revenue stream | Buyer / payer | How money arrives | Evidence | Quality read |
|---|---|---|---|---|
| ER-alternative care | Payer, health system, risk-bearing entity | Episode reimbursement or contracted program economics | Official services and strategy pages | Core but economically opaque |
| Hospital-at-home episodes | Hospital / health system with reimbursement pathway | Inpatient-equivalent reimbursement or partner contract | Merger and strategy materials | Potentially high-value, integration heavy |
| Transitional care / readmission avoidance | Health system or payer | Program fees and downstream shared-value logic | Capabilities and patient pages | Helpful recurring workflow attachment |
| Technology / enablement layer | Health systems | Bundled or embedded in enterprise deployment | CESIA and 2026 strategy framing | Likely important but not separately disclosed |
| Patient out-of-pocket / copay exposure | Individual patient | Insurance-linked visit responsibility | Cost and coverage page | Commercially relevant but not the core driver |
The public record supports the revenue categories more clearly than the revenue mix percentages.
[CI001, CI002, CI003, CI004, CI020, CI021]| Surface | What is public | What is private | Implication | Confidence |
|---|---|---|---|---|
| Patient affordability page | Insurance coverage and affordability framing | Actual payer rates and enterprise pricing | Supports institutional reimbursement thesis but not benchmark pricing | Medium |
| Hospital / payer contracting | Not publicly priced | Episode rates, guarantees, shared-savings terms | Prevents clean competitor comparison | Low |
| Technology / enablement packaging | Strategy narrative only | Module pricing and attach rates | Could drive margin leverage if separable | Low |
| Consumer membership analog | Not core to DispatchHealth | N/A | Shows why One Medical is only an adjacency | High |
| Geographic reimbursement mix | Not public | State and payer realization rates | Critical to economics, absent from open record | Low |
Pricing opacity is a core diligence finding, not just a missing detail.
[CI002, CI003, CI004, CI022, CI032, CI033]How care demand translates into institutional revenue surfaces.
The bridge is conceptual because public sources do not disclose exact contract waterfalls or claim adjudication logic.
[CI001, CI002, CI004, CI020, CI021, CI032]4.2 Cost base is labor and logistics heavy
The strongest financial inference available from public sources is that DispatchHealth has a labor-heavy, logistics-heavy cost structure. Mobile care teams, command-center staff, routing, diagnostics, supply movement, and software all sit inside the same operating model. That is a very different shape from a telehealth marketplace or software-only workflow vendor. It explains why investors should expect meaningful fixed and semi-variable operating cost even if public gross margin data is absent. Public workforce proxies support that read while also exposing uncertainty. Growjo estimated 1,287 employees, Unify shows a workforce mix tilted toward healthcare, engineering, and business operations, and Healthcare Dive cited more than 2,200 employees around the merger. The precise denominator is unclear, but every visible signal points toward a large service-delivery base. The 2025 layoffs and market scale-backs further suggest management is actively tuning footprint and productivity rather than simply adding capacity.[CI005, CI006, CI007, CI008, CI019, CI024]
| Cost / efficiency driver | Public signal | Likely effect | Evidence strength | Diligence ask |
|---|---|---|---|---|
| Clinical field labor | Large healthcare workforce implied | Major variable cost | Medium | Request visits per field team and productivity by market |
| Routing and logistics | CESIA and mobile-delivery model emphasized | Raises fulfillment complexity and cost | High | Request route density and supply cost per episode |
| Diagnostics / mobile assets | Imaging and lab support highlighted; imaging business later divested | Can improve differentiation but carries asset burden | Medium | Request owned vs partner asset economics |
| Command-center operations | Hospital-at-home operations require centralized oversight | Adds fixed overhead, may improve scale efficiency | High | Request command-center staffing ratios |
| Reimbursement timing | Claims and enterprise settlement likely lag service delivery | Working-capital pressure | Medium | Request DSO / claims-payment timing by payer |
| Market utilization | Layoffs suggest uneven density across markets | Low-density markets probably margin dilutive | Medium | Request contribution margin by market cohort |
No audited unit economics are public; rows summarize the main cost and efficiency levers investors should interrogate.
[CI005, CI006, CI007, CI008, CI019, CI024]Publicly visible cost and efficiency levers inside one home-care episode model.
This flow names the visible cost stack but does not quantify it because public margins are unavailable.
[CI006, CI007, CI018, CI024, CI025, CI029]4.3 Capital support exists, but the live balance sheet is opaque
DispatchHealth has clearly attracted substantial outside capital. Fierce covered a meaningful 2020 Series C, while the 2022 financing narrative described a much larger Series E and structured debt package. That package was explicitly tied to expansion, platform development, and capability buildout. In other words, external investors have already funded the thesis that this company needs both operating scale and technical infrastructure to win. What the public record does not provide is a current balance-sheet bridge. There is no accessible disclosure of cash on hand, monthly burn, covenant package, current debt draw, or runway. Alternative-data providers fill the void with modeled revenue and valuation numbers, but those estimates conflict and should not be mistaken for financial statements. The sale of the imaging business to TridentCare is a useful signal of portfolio reshaping, yet it still does not answer the core question of whether the combined business is self-funding, cash consumptive, or preparing for another capital event.[CI009, CI010, CI011, CI012, CI013, CI014]
| Capital item | Public evidence | Amount / status | Use / implication | Confidence |
|---|---|---|---|---|
| 2020 Series C | Fierce Healthcare | 135.8M | Scaled the business before hospital-at-home expansion | Medium |
| 2022 Series E | Medhealth Outlook | 259M equity | Funded expansion and platform development | Medium |
| 2022 debt financing | Medhealth Outlook | ~75M plus 75M contingent | Confirms structured capital in stack | Medium |
| Current cash / runway | Not public | Unknown | Major diligence blocker | Low |
| Next financing need | Not public | Unknown timing | Likely linked to post-merger proof and margin stability | Low |
Capital support is evident, but the live balance-sheet position is not.
[CI010, CI011, CI012, CI013, CI017, CI018]Third-party revenue and valuation surfaces are wide and low-confidence.
These are not audited ranges; they are single-source public surfaces shown only to highlight uncertainty and drift across valuation narratives.
[CI008, CI009, CI015, CI016]4.4 Financial verdict: strategically backed, numerically under-disclosed
The public evidence supports a coherent strategic financial story even if it fails to support a clean model. DispatchHealth is chasing large institutional budgets, has attracted serious capital, and operates in a category where buyers care about avoided hospital cost and readmission pressure. Those are all positives for revenue quality and category durability. The model also has at least some software leverage through CESIA, workflow automation, and enterprise enablement. But the missing pieces are central to underwriting. Investors still cannot reconcile post-merger revenue, margin, burn, debt load, or market-level contribution economics from open sources. That makes valuation discipline especially important. The right financial frame is therefore neither “great software multiple” nor “broken services company.” It is a capital-intensive healthcare operations platform with partial software leverage and meaningful disclosure gaps that must be closed before an aggressive price can be justified. Even adjacent public-company filings suggest home-based care projections can weaken quickly when payer mix or customer shape changes.[CI021, CI022, CI023, CI034, CI035, CI036]
| Question | What public sources provide | What is missing | Why it matters | Priority |
|---|---|---|---|---|
| Revenue today | One modeled estimate from Growjo | Company-verified revenue by service line | Needed for valuation and margin context | Critical |
| Gross margin | Narrative only | Contribution and gross margin by service line | Determines whether software leverage is meaningful | Critical |
| Burn / runway | No public disclosure | Cash balance, burn, covenant headroom | Determines financing risk | Critical |
| Utilization | Scale anecdotes only | Visits, admissions, census, repeat usage by market | Links cost base to revenue productivity | High |
| Headcount denominator | Conflicting third-party counts | Management-confirmed FTE and contractor split | Affects productivity proxies and reorg read | High |
This table is intentionally gap-heavy because numeric under-disclosure is the core limitation of the public record.
[CI008, CI015, CI016, CI017, CI022, CI023]Positive institutional demand can be offset by heavy operating requirements and disclosure gaps.
The map is a directional cash-flow logic model rather than a quantified forecast.
[CI007, CI018, CI019, CI021, CI023, CI024]05Product & Technology
5.1 Product definition: a full-stack care-at-home operating system
DispatchHealth’s product should be read as a workflow system for moving acute and post-acute episodes out of facilities and into the home. In practice that means the offering is not one thing. It combines patient intake, clinical triage, field-staff dispatch, mobile diagnostics, home-based treatment, follow-up recovery workflows, and enterprise coordination for the institutions paying for or operating the program. The company’s official materials increasingly present this as a complex-care-at-home platform rather than as a house-call brand. That framing helps explain the module map. ER-alternative visits address the first acute encounter, hospital-at-home extends into higher-acuity episodes, and transitional care addresses recovery and readmission risk. CESIA and related workflow tooling tie those services together. Even ancillary services like imaging, specialty networks, and pharmacy or lab coordination matter because they reduce the number of times an episode has to bounce back into a facility.[CE001, CE002, CE007, CE008, CE027, CE028]
| Module / asset | What it does | Buyer value | Evidence | Current read |
|---|---|---|---|---|
| ER-alternative care | Treats serious but home-manageable episodes quickly in the home | Avoids ED utilization and improves convenience | Capabilities and patient pages | Core current product |
| Hospital-at-home | Extends into inpatient-alternative care at home | Supports bed-capacity relief and higher-acuity programs | Merger and capabilities materials | Core growth module after Medically Home |
| Transitional care | Supports post-discharge recovery and readmission avoidance | Improves continuity and lowers downstream utilization | Capabilities and strategy materials | Core current product |
| CESIA workflow layer | Coordinates logistics, resources, workflows, and integrations | Improves scalability and operational consistency | Technology and strategy pages | Core orchestration asset |
| Ancillary diagnostics / networks | Mobile lab, imaging access, specialty coordination | Expands what can be treated at home | Capabilities page and TridentCare note | Partly owned historically, partly partnered |
The module set reflects the public product surface after the merger and 2026 strategy reset.
[CE001, CE002, CE007, CE008, CE020, CE027]| Use case | Trigger | Workflow | Clinical need | Why DispatchHealth fits |
|---|---|---|---|---|
| ER-alternative episode | Acute but non-life-threatening condition | Same-day triage, dispatch, in-home treatment, discharge plan | Rapid response and diagnostics | Avoids facility use while keeping hands-on care |
| Hospital-at-home episode | Inpatient-eligible but home-manageable case | Hospital partner workflow, command center, home monitoring, escalation path | Higher-acuity oversight | Extends care-at-home into inpatient substitute |
| Transitional recovery | Post-discharge or high-readmission risk | Follow-up treatment, monitoring, coordination, recovery support | Continuity and readmission prevention | Ties first acute episode to downstream recovery |
| Payer-directed home episode | Plan or risk-bearing entity wants lower total cost | Member routing into home clinical workflow | Cost and quality management | Aligns with payer medical-cost goals |
| Health-system enablement | Partner wants to scale its own branded program | Software + operational design + local workflow integration | Institutional deployment | Matches 2026 B2B positioning |
Use cases emphasize workflow and buyer logic rather than diagnostic code lists.
[CE001, CE002, CE010, CE012, CE017, CE030]The DispatchHealth stack layers institutional demand, CESIA orchestration, field operations, and ancillary partner services.
The stack is logical rather than technical-source-code architecture because public materials describe functions, not infrastructure internals.
[CE001, CE002, CE003, CE004, CE007, CE017]5.2 Architecture blends software orchestration with local execution
The technology story is meaningful, but it is inseparable from operations. CESIA appears to handle logistics, resource matching, workflow automation, and EMR-linked coordination, while the clinical model requires mobile teams, supplies, scheduling, and escalation pathways in the field. This is a stronger architecture than a pure consumer app, but it also means product quality depends on local execution, not only code quality. The deployment evidence suggests real production use. MedStar, Regence, Saint Francis, and Valley Health all provide external proof that the company can be inserted into partner workflows. The Locus partnership further suggests that DispatchHealth can incorporate third-party monitoring or digital-health tools when needed. The combined picture is of a product that behaves like a deployable operating layer for hospitals and payers, not a narrow software widget. That also means implementation quality and partner onboarding discipline are part of the product, not just post-sale services.[CE003, CE004, CE005, CE006, CE009, CE010]
| Layer | Role | Owned vs partnered | Evidence | Constraint |
|---|---|---|---|---|
| CESIA software | Routing, matching, workflow automation, coordination | Owned platform layer | Technology page | Underlying stack details not disclosed |
| Clinical field teams | Bedside care execution in the home | Owned / managed operations | Capabilities and patient pages | Labor-intensive and market-local |
| EMR integration | Connects home episode to partner workflow | Likely mixed / integrated with customer systems | Technology page | Specific integrations not publicly listed |
| Monitoring / digital partners | Extends visibility and support where needed | Partnered in some cases | Locus partnership | Partner dependency introduces complexity |
| Ancillary diagnostics and imaging | Enables broader acuity in the home | Mixed owned / partner history | Capabilities plus TridentCare transaction | Asset strategy not fully public |
Architecture is described functionally because public materials focus on what the system does, not deep technical implementation.
[CE003, CE004, CE005, CE006, CE008, CE009]A partner or patient-triggered acute episode becomes an orchestrated in-home workflow.
This flow synthesizes company and partner descriptions of how episodes move through the system.
[CE001, CE005, CE010, CE017, CE029, CE030]DispatchHealth depends on payer and provider buyers, CESIA, field labor, and partner services working in sequence.
Dependencies are operational relationships inferred from public materials, not system-diagram exhaustiveness.
[CE003, CE006, CE009, CE010, CE016, CE017]5.3 Differentiation comes from workflow depth and enterprise fit
DispatchHealth’s strongest differentiation is not that it has the slickest patient front end. It is that it owns more of the hard middle of the workflow than most comparators. Versus Amazon One Medical, it operates at higher acuity and with far more logistics and clinical complexity. Versus Current Health, it presents more direct bedside-delivery ownership. Versus health systems building internally, it offers a preassembled mix of software, workforce practices, and partner networks. The roadmap appears to be moving further in that direction. The 2026 strategy update shifts emphasis toward helping health systems scale complex care at home, which implies deeper embedment, co-branded deployment, and better orchestration rather than a push toward self-serve consumer growth. The imaging divestiture is consistent with a product portfolio that can rebalance which asset layers are owned and which are partnered so long as the overall workflow still holds together. Historical app-launch materials also suggest the company has steadily deemphasized the consumer app as the center of the product story.[CE012, CE018, CE019, CE020, CE021, CE024]
| Theme | Evidence date | Signal | Stage | Implication |
|---|---|---|---|---|
| Merger integration into national platform | 2025-06 | Merger close narrative | Scaling | Broadens product scope and buyer story |
| Health-system enablement focus | 2026-07 | Refined market focus press release | Active strategic shift | Roadmap tilts toward B2B deployment |
| Saint Francis launch | 2026-02 | Named production launch | Live deployment | Shows continuing product rollout |
| Monitoring / partner extensibility | 2023-2026 visible partnership footprint | Ongoing capability extension | Active / partnered | Suggests modular rather than all-owned design |
| Technical disclosure depth | No public changelog or SLA artifact found | Disclosure gap | Unknown | Investors still need reliability evidence |
Public roadmap evidence comes from launches and strategy signals, not engineering release notes.
[CE011, CE012, CE020, CE021, CE023, CE024]5.4 Trust is solid on outcomes and accreditation, thinner on technical disclosure
The trust file is stronger than many private healthcare startups. DispatchHealth can point to ACHC accreditation, repeated outcomes metrics, and multiple named enterprise partners. That is valuable because this category is clinical and operationally risky by nature. A company does not get repeated hospital and payer deployments on story alone. Where disclosure remains thinner is in the classic software-risk layer. Public materials do not provide a formal uptime dashboard, detailed security certifications, API documentation, or explicit SLAs. Post-merger service pullbacks also remind investors that operating excellence must be maintained market by market. The right diligence conclusion is therefore constructive but incomplete: the public record supports product credibility and maturity, but not yet a clean audit of reliability, security posture, or deployment economics. It is a mature operating product with an immature public technical disclosure surface. That asymmetry should be closed in management diligence before underwriting an aggressive growth story.[CE013, CE014, CE015, CE016, CE022, CE023]
| Dimension | Public proof | What it supports | Gap | Risk implication |
|---|---|---|---|---|
| Clinical quality | ACHC accreditation | Operational rigor for in-home hospital care | No full external audit reviewed | Supports trust but not a full diligence substitute |
| Outcomes | 58% ER avoidance, 8.5% readmissions, 98% satisfaction | Product credibility and buyer confidence | Metrics are company-selected | Useful but should be re-verified in diligence |
| Partner proof | MedStar, Regence, Saint Francis launches | Shows production deployment | Renewal depth not public | Good trust signal for buyers |
| Security / privacy | EMR integration and healthcare workflow context | Implied PHI handling competence | No public certification or SLA list found | Creates diligence need on cybersecurity and uptime |
| Operational stability | Active 2026 launches after merger | Suggests product continuity | 2025 scale-backs show uneven execution risk | Maturity is real but not frictionless |
Trust evidence is stronger on care quality and partner proof than on classic software disclosure artifacts.
[CE010, CE013, CE014, CE015, CE016, CE022]The public file looks strong on care breadth and partner proof, but weaker on classic software transparency.
This matrix is an analytical maturity lens, not a benchmark survey.
[CE014, CE015, CE018, CE019, CE022, CE023]06Customers
6.1 The real customer is usually the institution, not the patient
DispatchHealth serves patients directly, but the more important customer frame is institutional. Health systems, payers, and other risk-bearing entities usually control the budget, referrals, or workflow access that make the home episode possible. The patient remains the end user and care recipient, but the economic relationship is typically mediated by coverage, referral logic, or enterprise program design. That distinction matters because it means customer analysis should focus less on app downloads and more on the strength of institutional proof. The scale signals support that framing. DispatchHealth said at merger close that the combined company served more than 50 enterprise customers and had treated more than 1.2 million people across more than 20 states. Those are meaningful numbers for a private healthcare operator. They do not prove revenue concentration or renewal quality, but they do show that the company has moved beyond pilot-stage novelty and into a sizable installed base. That is an important threshold because healthcare buyers usually do not tolerate immature operational proofs for acute episodes at scale over time today.[CU001, CU002, CU003, CU004, CU005, CU016]
| Segment | Economic buyer | End user | Channel | Why it matters |
|---|---|---|---|---|
| Health systems | Hospital / health-system leadership | Patients and clinicians | Direct enterprise partnership | Core buyer for branded care-at-home deployment |
| Payers / MA plans | Health plan or medical-management team | Members / patients | Covered member routing and partnerships | Controls covered lives and utilization steering |
| Risk-bearing entities / employers | Risk-bearing sponsor or employer partner | Employees or attributed members | Partner channel | Useful but less visible in current public narrative |
| Senior living / community partners | Facility operator or partner network | Residents | Partner channel | Can provide concentrated referral streams |
| Direct patient request path | Patient with coverage or self-pay exposure | Patient | Website / phone / local partner entry | Useful front door but not the main budget owner |
Rows separate budget owner, channel, and end user because those roles diverge in this market.
[CU001, CU002, CU005, CU016, CU017, CU020]| Metric | Public figure | Date | Source type | Interpretation |
|---|---|---|---|---|
| Enterprise customers | 50+ | 2025-06 | Official merger close statement | Meaningful institutional installed base |
| Patients treated since inception | 1.2M+ | 2025-06 | Official merger close statement | Shows cumulative demand and operating scale |
| Geography | 20+ states | 2025-06 | Official merger close statement | National but still selective footprint |
| New named launch | Saint Francis hospital-at-home | 2026-02 | Partner and news proof | Demonstrates ongoing deployment after merger |
| Retention / renewal | Not publicly disclosed | 2026 | Gap | Key missing underwriting metric |
Public adoption signals are solid at the top of the funnel but thin on cohort math.
[CU003, CU004, CU008, CU019, CU021, CU022]Patient-facing access is simple, but the economic journey runs through institutional coverage and partner workflows.
[CU001, CU005, CU009, CU016, CU017, CU027]Institutional adoption requires more gating than consumer healthcare apps.
Indexed funnel values are directional, not measured conversion rates.
[CU004, CU014, CU016, CU017, CU020, CU021]6.2 Named proof is solid across payer and provider channels
The strongest public customer evidence comes from named partners. MedStar provides health-system proof, Regence provides payer proof, and Saint Francis provides a fresh 2026 hospital-at-home launch. Valley Health adds another useful window because it publishes a patient-facing workflow that shows how the service is actually experienced: symptom intake, APP plus technician visit, prescriptions, and insurance billing support. Taken together, these sources show that DispatchHealth is not selling only an abstract concept. It is being embedded into real delivery and reimbursement contexts. Customer experience evidence is directionally positive but uneven. The official outcomes study and repeated operating metrics suggest strong satisfaction and clinically credible service. Consumer-review surfaces are weaker and noisier. BBB and RatingFacts add some complaint color, while the company’s own review pages were unavailable during this run. That means partner references deserve more weight than generic review websites when evaluating customer quality.[CU006, CU007, CU008, CU009, CU010, CU011]
| Account / partner | Customer type | Evidence | Freshness | What it proves |
|---|---|---|---|---|
| MedStar Health | Health system | Official partner announcement | 2024 | Provider-channel production proof |
| Regence | Payer | Official and partner newsroom announcements | 2023-2024 | Payer-channel proof and member-routing relevance |
| Saint Francis Health System | Health system | 2026 launch coverage plus partner page | 2026 | Fresh hospital-at-home deployment proof |
| Valley Health System | Partner distribution / workflow proof | Partner workflow page | Current page accessed 2026 | Customer-experience specificity and service depth |
| 50+ enterprise customers disclosure | Aggregate enterprise base | Official merger-close statement | 2025 | Portfolio breadth beyond a handful of logos |
Named proofs span provider, payer, and workflow-partner surfaces, improving reference quality.
[CU006, CU007, CU008, CU009, CU024, CU029]| Signal | What is public | Quality | What it implies | Gap |
|---|---|---|---|---|
| Patient satisfaction | 98% satisfaction cited repeatedly | Medium | Positive end-user experience signal | Company-selected metric |
| Clinical follow-through | 8.5% 30-day readmission rate cited | Medium | Implies trust and appropriate care continuity | Still management-provided |
| Consumer reviews | Mixed BBB / RatingFacts surfaces plus broken official review pages | Low | Open consumer sentiment is noisy | Not a clean cohort metric |
| Enterprise renewals | No public NRR / GRR / churn metric | None | Major gap | Need direct diligence |
| Reference quality | Named payer and health-system partners | High | Stronger than anonymous reviews | Still not a contract-renewal disclosure |
This table intentionally distinguishes between satisfaction proof and true retention math.
[CU010, CU011, CU012, CU013, CU018, CU025]Named institutional proof is much stronger than anonymous consumer-review evidence.
The matrix scores proof quality rather than customer happiness levels.
[CU007, CU008, CU010, CU011, CU012, CU013]6.3 Durability likely sits at the account level, but the math is private
Public sources do not disclose net retention, gross retention, or contract renewal rates, so customer durability cannot be measured directly. Still, the structure of the business suggests that enterprise relationships should be stickier than simple consumer app usage. Once a payer or health system integrates home-based acute care into care pathways, billing, staffing, and escalation workflows, the relationship becomes harder to replace than a casual digital-health subscription. Expansion also appears to be channel-driven. The 2026 strategy refinement sharpened the company around enabling health systems to scale care at home, which reads like a land-and-expand motion through institutional channels. Self-pay or direct consumer demand may still provide entry volume, but the real growth engine appears to be partner-enabled adoption. That customer architecture is attractive, but it also means channel dependence and slower enterprise sales cycles remain part of the thesis.[CU013, CU014, CU015, CU016, CU017, CU020]
| Question | Public read | Risk | Why it matters | Diligence ask |
|---|---|---|---|---|
| Land-and-expand motion | Likely yes through institutional channels | Medium | Channel structure can support growth but slows sales cycles | Request account expansion history by segment |
| Top-customer concentration | Unknown | High | Large institutional accounts could dominate economics | Request top-10 customer revenue share |
| Channel dependence | High on payer and provider partners | Medium-High | Growth depends on partner access and workflow embedment | Request referral mix and channel attribution |
| Service consistency by market | Mixed after 2025 scale-backs | Medium-High | Uneven density can hurt renewals and reference quality | Request market-level service metrics |
| Direct consumer resilience | Supportive but secondary | Medium | Helpful lead flow, but not the primary moat | Request direct-request conversion and repeat rates |
Concentration risk is mostly inferred because the public record omits customer-level economics.
[CU014, CU015, CU016, CU020, CU021, CU022]Indicative cohort view separating episodic patient reuse from stickier enterprise-partner relationships.
These are diligence framing proxies inferred from the episodic nature of care and the integration depth of enterprise channels; they are not disclosed company cohorts.
[CU013, CU014, CU015, CU017, CU022, CU023]6.4 Good proof file, incomplete underwriting file
The core customer verdict is positive. DispatchHealth has credible named references, a meaningful cumulative patient count, and a public enterprise-customer disclosure that is stronger than what many private healthcare startups provide. The partner mix also spans both sides of the market—providers and payers—which strengthens reference quality. The main problem is what remains missing. Investors still need account expansion rates, renewal dates, active-program counts, top-customer concentration, and market-level service consistency. The 2025 scale-backs are a reminder that not every local market may have scaled equally well. So the right diligence view is that DispatchHealth has real customer traction and strong reference quality, but the open record still stops short of proving durable cohort economics. Additional partner pages help confirm workflow depth, yet they still do not replace retention math. In practical terms, customer diligence now needs CRM-style evidence rather than more marketing collateral or cumulative patient counts.[CU019, CU024, CU025, CU026, CU033, CU034]
07Risks
7.1 Regulatory risk is lower than in 2024, but still not solved
The most obvious policy overhang was the federal hospital-at-home waiver. That risk improved materially when lawmakers extended the AHCAH framework through 2030. In that sense, DispatchHealth no longer faces the same near-term cliff risk that previously shadowed the category. But the risk did not disappear; it shifted. Monetization still varies by state, Medicaid support is limited, and parts of DispatchHealth’s service mix live outside a neat single reimbursement box. Legal visibility is less dramatic but still incomplete. No major public litigation or enforcement issue was surfaced in this run, yet the public record is too thin to treat that as dispositive. Investors should therefore treat regulation as manageable but still material: it is no longer a binary “waiver expires” problem, but it remains a messy coverage, compliance, and commercial-terms problem. The company does publish a meaningful privacy and legal disclosure surface, but those documents mainly prove policy intent, not operational performance. In healthcare, that distinction matters because documented policies can coexist with weak field execution or uneven payer realization.[CR002, CR003, CR004, CR005, CR027, CR038]
| Risk | Likelihood | Impact | Why it matters | Mitigation / ask |
|---|---|---|---|---|
| Uneven reimbursement outside core waiver logic | Medium-High | High | Not all service lines ride one stable national reimbursement path | Request payer-state mix and realization by service line |
| Medicaid hospital-at-home underdevelopment | High | Medium-High | Only a limited number of states reimburse in FFS Medicaid | Request Medicaid economics and roadmap by state |
| Waiver dependence remains material | Medium | High | Federal support improved but remains a foundational enabler for some programs | Track legislative and CMS guidance changes |
| Legal-disclosure thinness | Medium | Medium | Public record does not prove litigation absence or compliance depth | Request litigation, claims, and compliance representations |
| Clinical and documentation compliance burden | Medium | High | Healthcare delivery failures can affect payment and trust | Request audit results and quality incident logs |
Regulatory risk is more about uneven monetization and compliance than a single imminent cliff.
[CR002, CR003, CR004, CR005, CR027, CR029]Execution and model-opacity risks rank highest in the current public file.
Heatmap placements are ordinal underwriting judgments from the retained public evidence.
[CR001, CR002, CR003, CR006, CR008, CR013]7.2 Operational reliability is the central execution risk
DispatchHealth is not a low-friction digital product. It is a field-and-workflow business whose quality depends on staffing density, dispatch reliability, diagnostics access, escalation discipline, and local market efficiency. That makes operations the central risk axis. The 2025 scale-back and layoffs are the clearest public warning that integration and market density do not automatically work everywhere. Quality and reputation need to be read through that lens. Positive outcomes metrics and ACHC accreditation are meaningful mitigants, but they do not eliminate the risk of local execution failure. Consumer complaint pages, archived review snippets, and broken public review endpoints are noisy evidence, not thesis killers. Their real importance is that they remind investors that trust can be eroded by uneven service quality or weak public proof surfaces even when the top-line category story remains attractive. If service quality slips in only a handful of markets, the reputational effect can still travel across payer and provider relationships.[CR001, CR006, CR007, CR008, CR009, CR018]
| Risk | Likelihood | Impact | Signal | Mitigation / ask |
|---|---|---|---|---|
| Staffing and logistics complexity | High | High | Field-based care model plus market pullbacks | Request productivity, fill-rate, and on-time-arrival metrics |
| Local quality variance | Medium | High | Positive outcomes exist but market-level detail is absent | Request escalation and adverse-event rates by market |
| Post-merger footprint mismatch | Medium-High | High | 2025 layoffs and market scale-backs | Review closed-market postmortems and market density criteria |
| Security / uptime disclosure gap | Medium | Medium-High | No public SLA or certification packet located | Request security audits, uptime history, and incident logs |
| Reputation noise from complaints and broken review surfaces | Medium | Medium | BBB / review-site noise and broken official review pages | Audit complaint themes and patient-resolution process |
Operational risk is the dominant near-term underwriting concern.
[CR001, CR006, CR007, CR008, CR009, CR013]Several root risks compound through operations into trust, margins, and valuation support.
The map shows causal pressure flow, not a probabilistic model.
[CR001, CR003, CR006, CR010, CR013, CR014]7.3 Partner dependence amplifies both upside and downside
DispatchHealth depends heavily on partners and institutional channels. Payers and health systems control referrals, covered lives, and workflow embedment, so concentration or partner dissatisfaction could hit harder than in a broad self-serve product. The leaked Medically Home reporting also matters here: merger integration can introduce hidden fragility even when the strategic story is compelling. The same amplification applies to people and financial risk. Headcount ambiguity obscures the real shape of the organization, while valuation opacity and missing margin data make it hard to know how much operating slack the company has. If the model requires dense local execution, then weak economics, partner concentration, and org instability can reinforce each other quickly. That is why seemingly separate issues—labor morale, payer breadth, and cash visibility—should be treated as a connected risk cluster instead of isolated boxes.[CR010, CR011, CR012, CR013, CR014, CR015]
| Dependency | Risk | Severity | Why it matters | Monitoring ask |
|---|---|---|---|---|
| Health-system partners | Concentration or slower deployment | High | Institutional buyers control volume and workflow embedment | Request top-account share and deployment cadence |
| Payer / MA channels | Coverage or economics change | High | Payers shape monetization and referral flow | Request payer mix and realized gross margin by payer cohort |
| Merger integration with Medically Home assets | Hidden complexity or inherited weakness | High | Synergy thesis can fail operationally | Request integration scorecard and duplicate-cost bridge |
| Ancillary service partners | Coverage gaps in diagnostics / monitoring | Medium | Partner failures can reduce care scope or quality | Request vendor criticality map and fallback plans |
| Competitive ecosystem | Internal build and point solutions pressure economics | Medium-High | Partners may unbundle the stack | Request win-loss by buyer type |
Partner risk matters because the model is embedded inside local care and reimbursement ecosystems.
[CR010, CR011, CR015, CR016, CR023, CR024]| Risk | Severity | Signal | Why it matters | Diligence ask |
|---|---|---|---|---|
| Leadership and org-change risk | Medium-High | Post-merger restructuring and role shifts | Integration depends on management bench cohesion | Review retention plans and org design |
| Headcount ambiguity | Medium | Conflicting alternative-data counts | Obscures productivity and restructuring analysis | Request verified FTE/contractor headcount |
| Employee morale / recruiting drag | Medium | Glassdoor archive and broken review surfaces | Healthcare services depend on labor quality and retention | Review attrition and vacancy rates |
| Financial disclosure opacity | High | No clean revenue, margin, burn, or runway | Makes capital-risk underwriting weak | Request board-quality financial package |
| Valuation narrative drift | Medium-High | Alternative-data marks conflict with open record | Can distort entry discipline and downside analysis | Request last-round documents and cap table |
People and model risk interact because labor-heavy operations are unforgiving of org instability.
[CR009, CR010, CR013, CR014, CR024, CR031]DispatchHealth depends on institutional channels, care operations, and disclosure quality all holding together.
Dependencies are simplified to the nodes most important for underwriting.
[CR010, CR011, CR013, CR015, CR016, CR024]7.4 Mitigations exist, but they need measurement
There are real mitigants in the file. DispatchHealth still shows active launches, named partners, a sharper 2026 strategy, published outcomes, and ACHC accreditation. Those signals argue against an immediate collapse thesis. They suggest management is trying to narrow the operating envelope to where the company can win. But mitigations only matter if investors can measure them. The right monitoring set is practical: launches versus exits, payer breadth, customer concentration, staffing stability, service-level quality, and evidence of margin improvement after rationalization. The risk verdict is therefore elevated but investable. The company has enough proof to justify diligence, but not enough disclosure to justify complacency. A disciplined investor should push hard on dashboards, not just narratives. That is especially true because post-merger stories can look healthy in press releases long before operating data is truly stabilized across markets and service lines over time durably yet today.[CR017, CR019, CR020, CR025, CR026, CR035]
| Theme | What mitigates it | What to watch | Kill trigger | Priority |
|---|---|---|---|---|
| Policy | 2030 extension and category momentum | CMS / congressional changes; state reimbursement progress | Meaningful rollback or stalled monetization | High |
| Operations | ACHC accreditation and outcomes track record | Market exits, staffing stability, service levels | Renewed broad retrenchment | Critical |
| Customers | Named launches and partner proofs | Go-live cadence, renewal proof, concentration | Loss of major partner or stalled launches | Critical |
| Economics | Strategy narrowing toward higher-fit markets | Margin bridge, density, payer realization | No path to stable unit economics | Critical |
| Disclosure | Willingness to provide dashboards in diligence | Speed and depth of data room response | Management cannot substantiate basic metrics | Critical |
Kill triggers are designed for investment discipline, not operating management.
[CR017, CR018, CR019, CR020, CR025, CR026]08Valuation
8.1 The valuation file is real, but internally inconsistent
DispatchHealth is clearly valuable enough to keep attracting capital, but the open valuation record is not internally clean. The strongest company-scale proof is solid: merger-close materials described a combined platform with more than 50 enterprise customers, more than 1.2 million patients treated, and a footprint spanning more than 20 states. That is real operating relevance, not a slideware asset. The problem starts when price enters the picture. Forge reported a March 2025 Series E-1 financing at a $3.58 billion post-money valuation and then an April 2026 financing at a $703.5 million post-money valuation. PitchBook independently corroborates that completed financings occurred on both dates, even if it hides the economic terms. Notice contributes an $888.31 headline with almost no context, and Nasdaq Private Market confirms only that the company is private and tradable through secondary workflows. The conclusion is not that any one alternative-data page is correct. It is that observable price discovery is too dispersed to support blind reliance on a single headline mark.[CV001, CV003, CV004, CV005, CV006, CV007]
| Comparable / marker | Metric | Multiple / valuation / status | Relevance | Limitation |
|---|---|---|---|---|
| Forge Mar-2025 round | Post-money valuation | $3.58B on $106.88M Series E-1 | Best observable high-water private mark | Alternative-data and security-level context incomplete |
| Forge Apr-2026 round | Post-money valuation | $703.5M on $97.71M Series A-1 | Best observable low-end private marker | May reflect structure-specific pricing |
| Teladoc | Public P/S | 0.48x sales | Distressed digital-health floor | Different model and public distress |
| Option Care | Public P/S | 0.62x sales | Closest home-based care adjacency | Still not hospital-at-home identical |
| CVS / Humana / UNH | Public P/S band | 0.29x-0.77x sales | Strategic-buyer discipline band | Conglomerate mix muddies direct comparability |
| Best Buy | Public P/S | 0.44x sales | Current Health ownership / exit analog | Retail business dominates valuation |
Enumeration focuses on the most decision-relevant private markers and public comparables.
[CV003, CV004, CV005, CV014, CV015, CV016]How company proof, price signals, and risks combine into the final call.
The logic chain is a diligence framework rather than a disclosed company process.
[CV001, CV002, CV006, CV010, CV013, CV023]8.2 Public comps force a much tighter multiple frame
Because DispatchHealth does not publish audited financials, the public comp set matters more than it normally would. The available directional comps are imperfect, but they are still informative. Teladoc, Option Care, CVS, Humana, UnitedHealth, and Best Buy all trade at low trailing sales multiples, roughly 0.29x to 0.77x on the sources reviewed in this run. That is not a venture-style software band. It is the valuation environment into which any future DispatchHealth financing, strategic sale, or IPO-like exit must ultimately clear. That does not mean DispatchHealth deserves only public-comp valuation. A scaled in-home acute-care network with payer and provider embedment could justify a premium for scarcity and control value. But the same facts that create strategic value also create operational drag: field staffing, logistics, clinical escalation, reimbursement complexity, and local density matter more here than in a pure software model. Public-company transparency deserves its own premium too. Teladoc and CVS publish audited 10-Ks. DispatchHealth does not. Investors therefore need a meaningful discount for missing denominator data, not just a generic private-company illiquidity haircut.[CV010, CV013, CV014, CV015, CV016, CV017]
| Argument | Why it matters | Key evidence | What would change the view |
|---|---|---|---|
| Scaled strategic asset | 50+ enterprise customers and 1.2M+ patients mean the platform matters nationally | Merger-close materials and strategy update | If scale proves shallow or concentrated, premium falls |
| Strategic-investor history | Optum-linked and payer-adjacent capital implies external belief in category importance | Fierce 2020 round and Regence-style partner logic | If strategic partners are inactive, scarcity case weakens |
| Opaque denominator | No audited revenue or margin means price cannot be cleanly triangulated | Company pages versus public 10-K comp set | Audited 2025 bridge would strengthen pricing confidence |
| Operational heaviness | Care delivery deserves less multiple generosity than software | Capabilities page plus public comp band | Proven mature-market margins would soften this objection |
| Cap-structure complexity | 2022 debt/equity plus conflicting 2025-2026 marks can distort fair value | Medhealth and Forge / PitchBook | Full cap-table docs could explain dispersion |
Rows separate pro-thesis quality from anti-thesis price discipline.
[CV001, CV002, CV010, CV011, CV012, CV020]Assumed revenue multiple selection has an outsized effect on implied value for a private denominator.
This is an illustrative multiple sensitivity using a placeholder $1.0B revenue denominator because the actual current denominator is not public.
[CV013, CV021, CV027, CV028, CV039]8.3 A sensible range is below the 2025 headline and above the 2026 trough
The range work should be framed as underwriting, not as false precision. The March 2025 Forge mark is too fresh and too large to ignore; it tells us credible investors were willing to fund the company near the mid-$3 billions at that time. The April 2026 Forge datapoint is too low and too recent to ignore either; it tells us that something in the 2026 security, cap table, or performance arc materially changed the observable price. Between those points sits the investable question. The bear case is a reset story: investors treat DispatchHealth like a hard-to-scale care-delivery operator and anchor close to the 2026 observable trough, producing roughly $0.6-1.0 billion. The base case assumes the platform is strategically important and still growing, but that opacity and execution risk justify a large discount to the 2025 mark; that yields roughly $1.5-2.4 billion. The bull case requires audited proof that growth, density, and payer quality remained strong through 2025-2026, which can support something like $3.0-3.8 billion. In other words, the prior high mark is only defendable if diligence closes the gaps, not before.[CV004, CV005, CV025, CV026, CV027, CV028]
| Scenario | Assumptions | Valuation range | Key risks | Probability signal |
|---|---|---|---|---|
| Bear reset | 2026 financing is directionally representative; growth and margin quality disappointed | $0.6B-$1.0B | Reset, dilution, weak unit economics | Meaningful if 2026 round terms are punitive |
| Base prove-it | Scale is real, but opacity and execution risk still deserve a heavy discount | $1.5B-$2.4B | Cap-table surprises, concentration, margin gaps | Most supportable from current open evidence |
| Bull strategic control | Audited results show strong density, payer quality, and durable growth | $3.0B-$3.8B | Any sign of weak economics breaks the case | Requires excellent private diligence |
| Unacceptable entry | Buyer pays at or above the March 2025 mark without reconciling 2026 pricing | 3.5B+ | Overpaying into opaque structure | Should be rejected on current evidence |
Ranges are underwriting outputs for committee discussion, not management guidance.
[CV026, CV027, CV028, CV029, CV030, CV031]Open evidence supports a wide but investable valuation range.
Ranges are underwriting outputs, not observed market prices or company guidance.
[CV004, CV005, CV026, CV027, CV028, CV029]8.4 Recommendation: conditional interest only, with hard diligence gates
The valuation recommendation is straightforward. DispatchHealth looks strategically relevant enough to merit diligence, but not transparent enough to merit a blank-check entry price. A buyer should assume cap-table complexity, request the full 2025 and 2026 financing documents, and insist on audited 2025 revenue plus current market-level unit economics before discussing any price near the March 2025 Forge mark. Without that package, the right stance is conditional only. The biggest reason to stay engaged is that the company still combines real scale, named partner logic, and category scarcity. The biggest reason to stay disciplined is that the open record already shows competitor churn, post-merger stress, and a valuation spread too wide to dismiss as noise. That combination leads to one answer: continue diligence, but anchor negotiations well below the 2025 high-water mark unless management can reconcile the 2026 financing, prove durable growth, and show that the platform deserves a strategic-control premium today.[CV002, CV011, CV012, CV032, CV033, CV034]
| Field | Current call | Why | What changes the view | Decision implication |
|---|---|---|---|---|
| Recommendation | Conditional / research-more | Asset quality is real, price support is not yet clean | Audited 2025 results plus cap-table reconciliation | Stay engaged, do not pre-clear price |
| Confidence | Medium | Observable marks conflict and denominator is private | Better primary financial evidence | Avoid high-conviction sizing |
| Risk rating | High | Execution, cap-table, and pricing opacity compound each other | Proof of durable market-level economics | Demand downside protection |
| Valuation stance | Below March 2025 mark | Open record cannot justify paying peak observed mark today | Management proves premium economics and explains 2026 round | Anchor lower in negotiations |
| Likely exit path | Strategic M&A or structured private financing | Private-market routing is visible; IPO readiness is not | Audited public-company readiness package appears | Model returns conservatively |
This is a price-sensitive recommendation table, not a generic company-quality score.
[CV008, CV009, CV030, CV031, CV032, CV034]| Trigger | Threshold | Transmission to thesis | Action implication |
|---|---|---|---|
| 2026 financing terms look punitive | Cap-table docs show severe seniority, ratchets, or reset economics | Observed low-end mark becomes more economically real | Move to pass or very low bid |
| Audited revenue underwhelms | 2025 or 2026 run-rate is far below what premium pricing requires | Bull and base cases compress rapidly | Re-anchor to bear case |
| Market-level economics are weak | Mature markets still fail to show healthy contribution margins | Strategic scarcity no longer offsets operating heaviness | Require major discount |
| Customer concentration is high | A few payer or health-system accounts dominate the book | Downside becomes binary rather than diversified | Reduce interest materially |
| Execution stress persists | More layoffs, exits, or integration disruption appear | Peak mark looks stale rather than durable | Pause investment process |
These are kill triggers because each one directly impairs the assumptions needed to defend even the base case.
[CV024, CV025, CV026, CV027, CV035, CV036]| Topic | Missing evidence | Why it matters | Owner or diligence path |
|---|---|---|---|
| Audited 2025 financials | Revenue, gross margin, EBITDA, cash, and 2026 bridge | Needed to replace guesswork with a denominator | CFO diligence pack and auditor materials |
| 2025 / 2026 financing docs | Stock purchase agreements, cap table, preferences, conversion rights | Needed to reconcile the $3.58B and $703.5M markers | Finance + counsel room |
| Market-level unit economics | Mature versus new market contribution margins and density curves | Determines whether strategic premium is earned | Ops and FP&A workstream |
| Customer concentration and retention | Top accounts, renewal schedule, churn, mix by payer and provider | Tests fragility of enterprise proof | Commercial and account analytics |
| Clinical quality and incident trends | Escalations, readmissions, complaints, and incident history | Execution risk can cap valuation fast | Clinical operations and compliance review |
Each ask could move the acceptable price, not just the narrative comfort level.
[CV010, CV020, CV033, CV034, CV035, CV036]The asset scores high on strategic relevance and lower on evidence quality and price support.
Scores are a synthesis of the evidence in this chapter rather than company-provided KPIs.
[CV001, CV010, CV021, CV024, CV033, CV039]Disclaimer
This report is an analytical research product generated by an automated diligence research system as of August 20, 2026. It relies on publicly available materials, company statements, partner disclosures, market-data services, filings, and independent reporting. Private-company financials and financing terms have not been independently verified with management. This report is not investment advice or a solicitation to buy or sell securities; readers should perform their own diligence before making investment decisions.
Evidence index
| ID | Statement | Confidence | Sources |
|---|---|---|---|
| CO001 | DispatchHealth was founded in 2013 in Denver to deliver high-acuity medical care in the home as an alternative to facility-based emergency and hospital care. | Medium | SO018, SO019, SO020 |
| CO002 | Mark Prather and Kevin Riddleberger co-founded DispatchHealth after seeing waste and avoidable facility use in emergency medicine workflows. | Medium | SO019, SO020, SO021 |
| CO003 | Becker’s reported that DispatchHealth began as True North Health Navigation before rebranding under the DispatchHealth name. | Medium | SO020 |
| CO004 | Alta Partners described the original operating model as in-home nurse-practitioner care that began in Denver and expanded into multiple mobile care platforms. | Medium | SO018 |
| CO005 | Jennifer Webster is the current CEO of DispatchHealth. | High | SO004, SO008, SO026 |
| CO006 | DispatchHealth elevated Erin Bartley to president in July 2026 after using her as a core integration leader during the Medically Home combination. | High | SO010, SO005 |
| CO007 | Mark Prather shifted from the founder-CEO role into co-founder and executive chair by the March 2025 merger announcement. | Medium | SO007, SO006 |
| CO008 | The post-merger leadership bench includes Bill Kramer as chief legal officer, David Wilkinson as chief financial officer, Erin Bartley in a senior operating role, and Pippa Shulman as chief medical officer. | Medium | SO008, SO010 |
| CO009 | DispatchHealth’s current positioning is an enablement company for health systems and risk-bearing providers rather than only a direct-to-consumer house-call brand. | Medium | SO009, SO002 |
| CO010 | After the merger, DispatchHealth publicly grouped its offering into ER-alternative care, hospital-alternative care, and transitional care. | High | SO008, SO027 |
| CO011 | The CESIA platform is described as an automation and logistics layer that integrates with any EMR and coordinates command-center visibility, care planning, and in-home resource matching. | High | SO003, SO009 |
| CO012 | DispatchHealth says its on-demand clinical workforce is specifically trained for complex in-home care and can be offered as a full service or as a modular capability. | Medium | SO002, SO009 |
| CO013 | DispatchHealth and Medically Home announced a definitive merger on March 18, 2025 and said the combined platform would reach 50 major metropolitan areas and nearly 40 health systems. | High | SO007, SO028, SO027 |
| CO014 | The companies closed the merger in June 2025 and confirmed operation under the DispatchHealth brand. | High | SO008, SO029, SO030 |
| CO015 | DispatchHealth said the combined company supports more than 50 enterprise customers and operates in more than 20 states. | Medium | SO008 |
| CO016 | DispatchHealth said it had treated more than 1.2 million people since inception by the time of the merger and still reported 58 percent ER avoidance, an 8.5 percent 30-day readmission rate, 98 percent satisfaction, and about $1.5 billion in medical cost savings. | High | SO007, SO008, SO012 |
| CO017 | The 2023 white paper said DispatchHealth’s hospital-alternative care study covered more than 1,000 patients over 18 months and reported readmission performance nearly 50 percent below the national average. | Medium | SO012 |
| CO018 | The white paper also said net promoter scores exceeded 93 and 96 percent of caregivers preferred the at-home model. | Medium | SO012 |
| CO019 | DispatchHealth received ACHC’s first in-home hospital care accreditation in November 2024. | Medium | SO011 |
| CO020 | MedStar Health expanded its DispatchHealth partnership to Baltimore for ER-alternative care at home in 2024. | Medium | SO013 |
| CO021 | Regence announced a 2024 partnership with DispatchHealth to deliver in-home care to members in the Pacific Northwest. | Medium | SO014, SO031 |
| CO022 | Locus Health and DispatchHealth announced a partnership to connect remote monitoring and in-home service coordination. | Medium | SO015 |
| CO023 | DispatchHealth launched a refined market focus in July 2026 that emphasized B2B enablement for branded customer programs. | High | SO009, SO032 |
| CO024 | The 2026 strategy release described CESIA as drawing on more than ten years of real-world encounter data and strategically embedded AI. | Medium | SO009 |
| CO025 | The 2022 financing article said DispatchHealth raised more than $330 million through a $259 million Series E plus debt commitments led by Optum Ventures and supported by Humana and Blue Shield of California. | Medium | SO022 |
| CO026 | Fierce Healthcare reported that the 2020 Series C totaled $135.8 million and included Optum Ventures, Oak HC/FT, Humana, Alta Partners, Questa Capital, and Echo Health Ventures. | Medium | SO021 |
| CO027 | Open public sources do not cleanly corroborate the user-supplied March 2025 $160 million round and $3.7 billion valuation beyond low-transparency alternative-data pages. | Low | SO033, SO034 |
| CO028 | Growjo still showed a March 2021 valuation anchor of about $1.7 billion rather than a post-2022 or post-2025 disclosed mark. | Low | SO023 |
| CO029 | Home Health Care News said DispatchHealth had raised more than $700 million by September 2025. | Medium | SO024 |
| CO030 | Growjo estimated total funding at $403.2 million, showing that alternative-data providers materially disagree on capital raised. | Low | SO023 |
| CO031 | LeadIQ categorized DispatchHealth as a Denver-based company with 501 to 1,000 employees in early 2026. | Low | SO035 |
| CO032 | Unify’s departmental headcount breakdown implies a workforce of about 638 people, far below the 2,200-plus figure cited near merger announcement, so public headcount should be treated as unstable. | Low | SO036, SO026 |
| CO033 | Healthcare Dive reported that the combined company would employ more than 2,200 people immediately after the merger closed. | Medium | SO026 |
| CO034 | Home Health Care News reported that DispatchHealth exited Little Rock and scaled back services in nine other markets in September 2025 after the merger. | Medium | SO024 |
| CO035 | The same report said management described the market exits and workforce adjustments as part of aligning to a more focused portfolio. | Medium | SO024 |
| CO036 | The archived Glassdoor overview still showed a 3.7 out of 5 employee rating, 198 reviews, and a 1001 to 5000 employee range, underscoring that labor sentiment and workforce data are directionally useful but stale. | Low | SO025 |
| CO037 | DispatchHealth’s cost page says co-pays for same-day visits typically range from $0 to $45 when covered by insurance. | Medium | SO016 |
| CO038 | The patient page says access depends on ZIP-code availability, acuity triage, and clinician capacity rather than guaranteed universal same-day coverage. | Medium | SO017 |
| CO039 | Several current company pages no longer provide a stable public patient-review landing page, which is a minor but real documentation-quality gap for customer-proof discovery. | Medium | SO037, SO038 |
| CO040 | DispatchHealth’s official materials and partner releases consistently position health systems, payers, and value-based entities as the key commercial customers rather than self-pay consumers. | High | SO007, SO008, SO009, SO014 |
| CM001 | DispatchHealth competes in a combined complex-care-at-home category spanning ER-alternative, hospital-at-home, and transitional-care episodes rather than a single narrow telehealth market. | High | SM002, SM003, SM004 |
| CM002 | The most relevant included spend is acute and post-acute episode management that can move from emergency departments, inpatient floors, or skilled nursing pathways into the home. | High | SM002, SM021, SM022 |
| CM003 | Excluded spend includes low-acuity virtual triage, routine home-health visits without acute escalation, and broad consumer primary-care subscriptions. | High | SM027, SM021, SM004 |
| CM004 | Key status-quo substitutes are the emergency department, inpatient admission, skilled nursing discharge, and fragmented home-health coordination. | High | SM022, SM023, SM028 |
| CM005 | CMS launched the Acute Hospital Care at Home initiative in November 2020 and Congress extended associated flexibilities through September 30, 2030 in the 2026 appropriations law. | High | SM018, SM019 |
| CM006 | AHCAH lets participating hospitals bill inpatient-level care delivered at home under waiver authorities instead of requiring all nursing services to remain on premises. | High | SM018, SM021 |
| CM007 | CHCS said hospitals under AHCAH receive the same reimbursement levels for inpatient care as for hospital-at-home care. | Medium | SM021 |
| CM008 | CHCS reported that 398 hospitals across 39 states had received AHCAH waivers as of April 2025. | Medium | SM021 |
| CM009 | CHCS also reported that only 12 state Medicaid agencies reimbursed hospital-at-home for fee-for-service Medicaid enrollees as of 2025. | Medium | SM021 |
| CM010 | The policy model generally requires at least two daily in-person visits by registered nurses or community paramedics and immediate remote access to the care team. | Medium | SM021, SM020 |
| CM011 | CMS said AHCAH data now covers nearly five years and includes admissions, escalations back to the hospital, unanticipated mortalities, and claims-linked beneficiary information. | Medium | SM018 |
| CM012 | Peer-reviewed reviews describe hospital-at-home as a high-value model with lower or comparable mortality, lower readmissions in many cohorts, lower complication rates, and meaningful cost savings versus brick-and-mortar care. | High | SM022, SM023 |
| CM013 | The high-value review cited randomized evidence showing overall cost reductions of roughly 38 percent in one U.S. model. | Medium | SM022 |
| CM014 | The scoping review described strong evidence on patient and caregiver experience, clinical safety, and lower costs, while also highlighting implementation difficulty. | High | SM023, SM031 |
| CM015 | Mordor Intelligence estimated the global hospital-at-home market at about $42.08 billion in 2026 with a path to roughly $61.55 billion by 2031. | Medium | SM024 |
| CM016 | The Insight Partners estimated a somewhat smaller 2025 global market of about $37.17 billion and a path to $72.84 billion by 2034. | Medium | SM025 |
| CM017 | DispatchHealth and Medically Home used an even larger, more expansive category framing by citing Chilmark research that pointed to a $300 billion hospital-at-home market by 2028. | Medium | SM001, SM026 |
| CM018 | Those estimates are not directly comparable because they mix global market forecasts, category-adjacent service layers, and different definitions of what counts as hospital-level home care. | Medium | SM024, SM025, SM001 |
| CM019 | DispatchHealth’s SAM is narrower than the broad TAM because the company focuses on high-acuity episodes that require logistics, mobile diagnostics, staffing, and reimbursement sophistication. | High | SM004, SM005, SM021 |
| CM020 | A practical SAM boundary centers on health systems, payers, and risk-bearing entities willing to outsource or co-build ER-alternative, hospital-at-home, and transitional programs. | High | SM003, SM002, SM008 |
| CM021 | Public sources do not provide enough pricing, win-rate, or utilization data to calculate a precise SOM for DispatchHealth. | Low | SM003, SM016, SM017 |
| CM022 | Health systems are natural buyers because hospital-at-home can free inpatient capacity, preserve brand control, and reduce avoidable facility utilization. | High | SM003, SM001, SM030 |
| CM023 | Payers and value-based entities are natural buyers because the model promises lower total cost of care, reduced readmissions, and lower ER use. | High | SM001, SM002, SM008 |
| CM024 | The end users are patients with serious but home-manageable conditions, their caregivers, and the clinicians or command-center teams managing the episode. | High | SM010, SM023, SM005 |
| CM025 | Adoption is strongest among older adults, medically complex members, high-readmission cohorts, and hospitals facing bed-capacity pressure. | High | SM022, SM023, SM021 |
| CM026 | Growth drivers include aging-in-place preferences, health-system capacity constraints, value-based-care economics, and the growing operational evidence base for home-based acute care. | High | SM001, SM022, SM024 |
| CM027 | The 2026 waiver extension materially reduced near-term regulatory uncertainty and should support provider investment decisions. | High | SM019, SM018 |
| CM028 | Category constraints still include state-by-state reimbursement variation, staffing and logistics complexity, command-center requirements, and integration with hospital EMRs and discharge workflows. | High | SM005, SM021, SM023 |
| CM029 | Medicaid adoption remains underdeveloped relative to Medicare and Medicare Advantage, limiting national universality for the category. | Medium | SM021 |
| CM030 | Home Health Care News noted that waiver uncertainty caused some organizations to delay adoption during 2025, showing that policy duration still affects commercial behavior. | Medium | SM017 |
| CM031 | DispatchHealth’s market also includes episodes that sit outside the strict inpatient-waiver definition, especially ER-alternative and transitional care services sold through payer and health-system contracts. | High | SM002, SM009, SM010 |
| CM032 | The company’s July 2026 B2B repositioning underscores that DispatchHealth is targeting institutional budget holders rather than pure self-pay consumer demand. | High | SM003, SM029 |
| CM033 | The care model is operationally heavy because it requires clinical staffing, supply routing, mobile diagnostics, remote monitoring, and real-time communications rather than lightweight app distribution alone. | High | SM004, SM005, SM002 |
| CM034 | Market-research estimates are useful for TAM direction but not for underwriting unit economics because they do not reveal state mix, acuity mix, or reimbursement realization rates. | Medium | SM024, SM025 |
| CM035 | The broad evidence base supports category viability, but public data still under-specifies how much of the opportunity is truly outsourceable to a partner like DispatchHealth versus retained internally by health systems. | Medium | SM023, SM021, SM003 |
| CM036 | Medicaid-focused evidence specifically emphasizes the need for more tailored program design for dually eligible and economically disadvantaged patients. | Medium | SM021 |
| CP001 | DispatchHealth competes most directly with other complex-care-at-home operators, care-at-home infrastructure vendors, and site-of-care optimization platforms rather than with pure telehealth apps. | High | SP002, SP003, SP018 |
| CP002 | The enduring status-quo substitutes are emergency departments, inpatient admissions, skilled nursing discharges, and fragmented home-health coordination. | High | SP011, SP012, SP019 |
| CP003 | Internal build by health systems remains a real competitor because AHCAH legitimized hospital-operated care-at-home programs. | High | SP009, SP010, SP003 |
| CP004 | CareCentrix is strongest in post-acute coordination and site-of-care optimization, but public materials do not show the same owned high-acuity bedside-delivery model as DispatchHealth. | High | SP018, SP019, SP004 |
| CP005 | Amazon One Medical offers membership-based primary care, telehealth, and in-person clinic access, which sits materially lower on acuity than DispatchHealth hospital-alternative care. | High | SP020, SP022 |
| CP006 | Amazon's pricing is visible to consumers through annual membership disclosures, which makes its packaging more transparent than DispatchHealth enterprise contracting. | High | SP020, SP021 |
| CP007 | Current Health is best understood as an enabling platform for remote monitoring and hospital-at-home workflows rather than a national field-clinician dispatch model. | High | SP023, SP025 |
| CP008 | Best Buy sold Current Health back to its co-founder in July 2025 after strategic headwinds in home health, which signals category churn rather than settled ownership structures. | Medium | SP024, SP025 |
| CP009 | Contessa Health's public site saying the website is no longer active weakens its visibility as a live independent competitor in 2026. | Medium | SP026 |
| CP010 | DispatchHealth's merger with Medically Home broadened its scope from mobile urgent and transitional care into a more national hospital-at-home platform. | High | SP001, SP002, SP031 |
| CP011 | CareCentrix competes more on payer workflow and discharge orchestration than on branded in-home acute bedside care. | High | SP019, SP018 |
| CP012 | Consumer distribution appears strongest at Amazon One Medical because Amazon can package One Medical through Prime and a national consumer brand. | High | SP022, SP020 |
| CP013 | Current Health appears stronger on enabling technology and monitoring infrastructure than on direct consumer brand or field-delivery density. | High | SP023, SP025 |
| CP014 | Public category pricing is opaque for most enterprise care-at-home vendors, making buyer-level contracting and margin comparisons difficult. | High | SP029, SP018, SP023 |
| CP015 | DispatchHealth publishes consumer-facing insurance and visit-affordability messaging, but not a general enterprise rate card. | High | SP029, SP030 |
| CP016 | Switching costs arise from EMR integration, staffing workflows, command-center processes, quality reporting, and payer or health-system contract integration. | High | SP005, SP003, SP010 |
| CP017 | Multi-homing is easier for lower-acuity front-door tools than for hospital-at-home operations that embed deeply in local clinical and logistics workflows. | High | SP020, SP005, SP012 |
| CP018 | Regulation and accreditation matter because hospital-at-home buyers need confidence in clinical quality, safety, and waiver compliance. | High | SP009, SP027, SP006 |
| CP019 | Logistics and staffing density create barriers to entry because high-acuity home care requires mobile diagnostics, routing, field teams, and command-center orchestration. | High | SP004, SP005, SP012 |
| CP020 | Retail and consumer-health players could pressure the lower-acuity edge of DispatchHealth's funnel, but public evidence does not show them matching its full hospital-alternative stack yet. | High | SP020, SP004, SP002 |
| CP021 | Some competitor relationships can also be complementary because hospitals may combine remote-monitoring vendors, coordination layers, and in-home clinical operators. | High | SP023, SP019, SP028 |
| CP022 | DispatchHealth's most defensible moat is operational integration across clinical delivery, logistics, and enterprise workflows rather than obvious hard-IP exclusivity. | High | SP003, SP005, SP004 |
| CP023 | The public record does not surface a strong patent moat; the observable edge is execution, trust, and customer integration. | High | SP005, SP003 |
| CP024 | Category structure remains unsettled because ownership, strategy, and operating models continue to change across peers. | High | SP025, SP026, SP016 |
| CP025 | DispatchHealth's own 2025 scale-backs show that operational difficulty can create openings for competitors even when the category thesis remains strong. | Medium | SP016, SP002 |
| CP026 | Public sources do not disclose a clean price-per-episode comparison across DispatchHealth, CareCentrix, Current Health, or internal hospital build options. | Low | SP029, SP018, SP023 |
| CP027 | Public sources are also not enough to compare competitor customer concentration or renewal quality with confidence. | Low | SP023, SP018, SP020 |
| CP028 | CareCentrix has deeper public messaging around home-benefit management and post-acute optimization than around bedside emergency-replacement care. | High | SP018, SP019 |
| CP029 | Amazon One Medical is more comparable as a lower-acuity front door and consumer membership product than as a true inpatient-alternative operator. | High | SP020, SP022, SP030 |
| CP030 | Current Health's stated work with health systems and more than 70,000 patients demonstrates relevance, but it still reads as infrastructure-first relative to DispatchHealth. | High | SP023, SP025 |
| CP031 | Contessa's inactive public site does not prove the business disappeared, but it does reduce visibility and confidence in it as a vibrant stand-alone go-to-market rival. | Medium | SP026 |
| CP032 | The strongest buyer-side alternatives to DispatchHealth are building internally, contracting point solutions, or steering patients back into incumbent facilities. | High | SP009, SP019, SP011 |
| CP033 | DispatchHealth's named outcomes, accreditation, and merger scale provide a stronger public trust file than most adjacencies aimed at lower-acuity digital care. | High | SP006, SP027, SP002 |
| CP034 | The merged company likely holds broader acute-home capabilities than any single adjacent comparator in this source set, but not an unassailable monopoly on buyer relationships. | High | SP002, SP018, SP023, SP020 |
| CP035 | Commoditization risk is real at the workflow layer because coordination, monitoring, and lower-acuity digital touchpoints can be unbundled by hospitals or vendors. | High | SP019, SP023, SP020 |
| CP036 | The best next diligence artifact would be a win-loss matrix by buyer type showing whether DispatchHealth wins on outcomes, breadth, speed, or total cost. | Low | SP003, SP018, SP023 |
| CP037 | Overall, DispatchHealth appears differentiated on high-acuity home delivery and enterprise orchestration, but the category remains vulnerable to internal build, adjacencies, and capitalized entrants. | High | SP002, SP003, SP025, SP020 |
| CI001 | DispatchHealth monetizes a mix of insurer-reimbursed home visits, hospital-at-home episodes, transitional care arrangements, and enterprise partnerships with health systems and payers. | High | SI004, SI003, SI002 |
| CI002 | The company is fundamentally episode- and contract-driven rather than a simple recurring-consumer-subscription model. | High | SI005, SI006, SI003 |
| CI003 | DispatchHealth publishes consumer-facing affordability and insurance messaging, but not a broad enterprise price card. | High | SI005, SI006 |
| CI004 | Its go-to-market motion appears enterprise-led, especially after the July 2026 repositioning toward enabling health systems to scale complex care at home. | High | SI003, SI002 |
| CI005 | The public record does not disclose enough sales-cycle or CAC data to calculate true sales efficiency. | Low | SI003, SI013 |
| CI006 | Major cost drivers likely include field-clinician labor, logistics, diagnostics, command-center staffing, payer contracting overhead, and software development. | High | SI004, SI007, SI032 |
| CI007 | The model is capital intensive because it combines provider operations with technology, routing, and home-based clinical infrastructure. | High | SI004, SI007, SI002 |
| CI008 | Growjo estimated DispatchHealth annual revenue at about $257.7 million, but that figure is third-party modeled and should be treated as low-confidence. | Low | SI013 |
| CI009 | Growjo also estimated total funding near $403.2 million and valuation around $1.7 billion in March 2021, which conflicts with later fundraising narratives. | Low | SI013, SI012 |
| CI010 | Medhealth Outlook described a 2022 financing package with a $259 million Series E plus roughly $75 million in debt and another $75 million contingent debt facility. | Medium | SI012 |
| CI011 | Fierce previously reported a $135.8 million Series C led by Optum Ventures in 2020, showing meaningful external capital support before the later Series E round. | Medium | SI011 |
| CI012 | The accessible open record therefore supports meaningful capital raised, but not a precise current fully diluted total with high confidence. | Medium | SI011, SI012, SI013 |
| CI013 | The 2022 financing narrative explicitly earmarked capital for market expansion, platform development, and broader in-home care capability buildout. | Medium | SI012 |
| CI014 | The acquisition of DispatchHealth's imaging business by TridentCare indicates portfolio reshaping and some willingness to divest non-core assets. | Medium | SI023 |
| CI015 | Alternative-data providers disagree materially on current valuation, with broken or low-reliability pages pointing above older public marks without strong corroboration. | Low | SI015, SI016, SI024, SI026 |
| CI016 | Forge and Notice provide secondary-market style valuation surfaces, but they do not substitute for a priced primary financing or audited financial disclosure. | Medium | SI016, SI024 |
| CI017 | Public sources do not disclose current cash on hand or burn rate, so runway cannot be underwritten from the open record alone. | Low | SI013, SI024, SI026 |
| CI018 | The next-round trigger is likely tied to proving stable post-merger integration, enterprise utilization growth, and an investable margin path rather than to consumer-user growth alone. | Medium | SI003, SI002, SI014 |
| CI019 | Layoffs and market scale-backs in 2025 imply the combined company is still aligning footprint and cost base rather than running at frictionless scale. | Medium | SI014, SI002 |
| CI020 | The merger raised the company's economic ambition from urgent care at home toward a broader institutional complex-care-at-home platform. | High | SI001, SI002, SI003 |
| CI021 | Revenue quality is helped by the fact that buyers are institutions solving expensive care pathways, not pure discretionary consumers. | High | SI003, SI010, SI009 |
| CI022 | Revenue quality is weakened by the fact that episode economics, reimbursement realization, and renewal depth remain private. | Medium | SI005, SI013, SI014 |
| CI023 | The biggest public financial red flag is opacity: no audited revenue, margin, burn, or cash balances are available in accessible sources. | Low | SI013, SI024, SI026 |
| CI024 | A second red flag is operational intensity and category margin pressure, because scaling field labor and logistics is costlier than scaling pure software alone and adjacent public filings show projections can reset downward. | High | SI004, SI007, SI014, SI033 |
| CI025 | Working-capital risk likely matters because reimbursement and enterprise settlement cycles can lag clinical delivery and field payroll. | Medium | SI005, SI030, SI031 |
| CI026 | Public sources do not reveal gross margin by service line, contribution margin by market, or utilization per field team. | Low | SI013, SI003 |
| CI027 | Unify's visible headcount breakout and Growjo's 1,287-employee estimate both imply a labor-heavy organization with significant non-software cost structure. | Medium | SI019, SI013 |
| CI028 | Healthcare Dive cited more than 2,200 employees at merger announcement, indicating that post-merger operating scale may be much larger than pre-merger alternative-data estimates. | Medium | SI021, SI013 |
| CI029 | That headcount divergence makes per-employee revenue and margin proxies unreliable without company-verified denominators. | Medium | SI013, SI021, SI019 |
| CI030 | Structured debt was explicitly part of the 2022 capital stack, confirming the company has used financing instruments beyond straight equity. | Medium | SI012 |
| CI031 | Public evidence does not show current debt outstanding, covenants, or amortization terms. | Low | SI012, SI026 |
| CI032 | The combination of enterprise buyers and reimbursement exposure likely creates uneven revenue timing across service lines and geographies. | Medium | SI003, SI010, SI005 |
| CI033 | The consumer-facing affordability message suggests patient out-of-pocket friction matters at the edge even if core economics are institutional. | Medium | SI005 |
| CI034 | Public financial artifacts are better at explaining strategic direction than at proving a precise margin path. | Medium | SI003, SI012, SI013 |
| CI035 | The strongest financial positive is category-aligned institutional demand backed by repeated external financing support. | High | SI003, SI011, SI012 |
| CI036 | The strongest financial blocker is that public evidence does not let an investor reconcile revenue, burn, and valuation after the 2025 merger and 2025 scale-backs. | Medium | SI013, SI014, SI024 |
| CI037 | Overall, DispatchHealth should be treated as a capital-intensive healthcare operations company with software leverage, not a pure software business that can be valued on SAAS heuristics alone. | High | SI004, SI007, SI012 |
| CE001 | DispatchHealth's product is best understood as complex care-at-home workflow infrastructure plus bedside clinical delivery, not as a standalone consumer app. | High | SE001, SE003, SE006 |
| CE002 | The visible product lines in 2026 are ER-alternative care, hospital-alternative care, transitional care, and CESIA-enabled enterprise workflow support. | High | SE001, SE003, SE006 |
| CE003 | CESIA is presented as the orchestration layer for logistics, resource matching, workflow automation, and integration across the care-at-home model. | High | SE002, SE003 |
| CE004 | The product stack mixes software with highly operational service components such as dispatch, staffing, supply routing, and in-home clinical execution. | High | SE001, SE002, SE023 |
| CE005 | Routing, logistics, and staffing are core product capabilities because the model requires getting the right clinician, equipment, and supplies into the home quickly. | High | SE001, SE002 |
| CE006 | Official technology materials say CESIA integrates with leading EMRs and helps streamline care-team workflows. | Medium | SE002 |
| CE007 | The product uses ancillary service layers such as mobile lab, pharmacy coordination, specialty networks, and imaging access to approximate facility-based care at home. | High | SE001, SE023 |
| CE008 | DispatchHealth's historical imaging footprint and later TridentCare transaction imply that imaging has been strategically important but not necessarily owned in its current form. | Medium | SE011, SE001 |
| CE009 | Locus Health partnership materials show that third-party monitoring and digital-health partners can sit inside the broader operating workflow. | Medium | SE010, SE002 |
| CE010 | Deployment into partner systems appears production oriented, with named launches and partner announcements rather than purely conceptual innovation language. | Medium | SE008, SE009, SE017, SE018 |
| CE011 | The Saint Francis 2026 launch is especially useful because it shows new hospital-at-home deployment after the merger and post-2025 retrenchment. | Medium | SE017, SE018 |
| CE012 | The July 2026 strategy update suggests the roadmap is tilting toward enabling health systems to scale complex care at home rather than emphasizing consumer brand expansion. | High | SE003, SE006 |
| CE013 | Support and reliability demands are intrinsically high because missed visits, supply issues, or integration failures can directly affect patient care and partner trust. | High | SE001, SE026 |
| CE014 | ACHC accreditation is a public trust marker that supports the hospital-at-home quality and operations story. | High | SE004, SE006 |
| CE015 | DispatchHealth repeatedly cites 58% ER avoidance, 8.5% 30-day readmissions, and 98% satisfaction as proof points for product effectiveness. | High | SE005, SE006 |
| CE016 | Public privacy and security specifics are comparatively thin; the company discusses technology and EMR integration more than formal security certifications or SLAs. | Medium | SE002, SE022 |
| CE017 | The product depends on health-system, payer, and ancillary partners because no single company can own every diagnostic, reimbursement, and monitoring function alone. | Medium | SE009, SE010, SE008 |
| CE018 | Compared with lower-acuity digital health products like Amazon One Medical, DispatchHealth is differentiated by field logistics, higher acuity, and institutional workflow depth. | High | SE014, SE001, SE002 |
| CE019 | Compared with infrastructure-only vendors like Current Health, DispatchHealth presents more direct bedside care delivery and workflow ownership. | High | SE013, SE001, SE006 |
| CE020 | The TridentCare transaction suggests some asset layers can be divested or partnered without undoing the broader care-at-home platform narrative. | Medium | SE011, SE003 |
| CE021 | The 2026 roadmap appears to emphasize enterprise enablement, scalable orchestration, and deeper integration of the merged Medically Home capability set. | Medium | SE003, SE006, SE019 |
| CE022 | Public adverse product signals include post-merger service pullbacks and the absence of detailed public uptime or deployment metrics. | Medium | SE015, SE003 |
| CE023 | Neither a public changelog nor detailed deployment volume metrics are available in the accessible record. | Low | SE019, SE020, SE002 |
| CE024 | No public SLA, uptime dashboard, or formal security certification list was found during this run. | Low | SE002, SE022 |
| CE025 | The product verdict is positive because DispatchHealth appears to have a real operating system for high-acuity care at home, not just marketing language. | High | SE001, SE002, SE006 |
| CE026 | That said, differentiation is more operational and workflow-based than based on obvious proprietary hardware or disclosed IP. | High | SE003, SE002 |
| CE027 | Patient-facing entry remains only one thin surface of the product; the core design point is institutional workflow embedment. | High | SE023, SE003 |
| CE028 | The capabilities page positions DispatchHealth as a blend of software, workforce, and partner-network orchestration rather than a single clinical service SKU. | High | SE001, SE002 |
| CE029 | Hospital-at-home deployment likely requires local clinical protocols, escalation pathways, and round-the-clock oversight in addition to software. | High | SE026, SE001, SE002 |
| CE030 | The company's official materials emphasize interoperability and workflow rather than detailed underlying technical stack disclosures. | Medium | SE002, SE003 |
| CE031 | The patient-access flow still centers on getting acute episodes treated at home quickly enough to avoid facility escalation. | High | SE023, SE001 |
| CE032 | Partner proofs with MedStar, Regence, and Saint Francis indicate the product can be embedded across both provider and payer channels. | Medium | SE008, SE009, SE017 |
| CE033 | The absence of public API, uptime, and cybersecurity detail is a diligence gap, not proof of weakness. | Medium | SE002, SE020 |
| CE034 | Broken consumer review pages suggest the company spends more public attention on enterprise messaging than on a polished open consumer proof surface. | Medium | SE024, SE025, SE003 |
| CE035 | Locations redirecting users into the patient flow reinforces that the front door is intentionally simple relative to the more complex enterprise back end. | Medium | SE021, SE023 |
| CE036 | Overall, the product and technology stack looks production-ready and differentiated, but public diligence still needs deeper evidence on security, reliability, and deployment economics. | High | SE003, SE002, SE008, SE009 |
| CU001 | DispatchHealth's economic customers are mainly health systems, payers, and risk-bearing entities, while patients are the end users receiving care in the home. | High | SU010, SU009, SU008 |
| CU002 | The company also serves partner channels such as senior living facilities, municipalities or response systems, and employers, at least in parts of its historical channel mix. | Medium | SU026, SU002, SU009 |
| CU003 | DispatchHealth said at merger close that the combined platform served more than 50 enterprise customers. | Medium | SU001 |
| CU004 | It also said the company had treated more than 1.2 million people across more than 20 states. | High | SU001, SU010 |
| CU005 | The customer story is therefore overwhelmingly institutional at the budget-owner level even when patient acquisition can begin through a direct request. | High | SU008, SU010, SU007 |
| CU006 | MedStar is named as a health-system partner for ER-alternative care expansion in Baltimore. | Medium | SU003 |
| CU007 | Regence is named as a payer partner delivering in-home medical care for members. | Medium | SU004, SU014 |
| CU008 | Saint Francis is a named 2026 hospital-at-home deployment, showing active newer customer proof after the merger. | Medium | SU013, SU012 |
| CU009 | Valley Health's service page shows a concrete customer-facing workflow with symptom intake, APP plus technician visits, prescription coordination, and billing support. | Medium | SU027 |
| CU010 | The outcomes study and repeated company metrics support strong customer experience claims, including 98% patient satisfaction and low readmission rates. | High | SU006, SU001 |
| CU011 | Public adverse review surfaces are weak but not pristine: RatingFacts shows mixed consumer complaints, BBB pages contain complaint and review surfaces, and official review pages were unavailable in this run. | Medium | SU016, SU017, SU018 |
| CU012 | The official patient-review surfaces returning 404 makes external customer-proof collection harder and slightly weakens the open consumer trust file. | Medium | SU028, SU029 |
| CU013 | No public NRR, GRR, renewal rate, or enterprise churn metric was found in accessible sources. | Low | SU010, SU019, SU022 |
| CU014 | Enterprise relationships appear more durable than consumer app interactions because deployments require workflow integration and local operating coordination. | High | SU010, SU003, SU004 |
| CU015 | Expansion appears to follow a land-and-expand motion across health systems, payers, and hospital-at-home programs rather than a pure direct-to-consumer viral loop. | High | SU010, SU001, SU012 |
| CU016 | Partner channels are important because they control referrals, covered lives, or branded program access, which is more valuable than self-pay app downloads. | High | SU004, SU003, SU026 |
| CU017 | Direct consumer demand still matters at the edge, but it appears subordinate to institutional channel access in the 2026 narrative. | High | SU008, SU007, SU010 |
| CU018 | The outcomes study implies meaningful repeat trust because low readmissions and strong satisfaction are prerequisites for repeat buyer references in clinical settings. | Medium | SU006, SU003 |
| CU019 | Public sources do not disclose the share of revenue or volume tied to any single customer, so concentration risk cannot be measured precisely. | Low | SU019, SU022, SU001 |
| CU020 | However, the enterprise nature of the customer base means concentration could be material even without a disclosed top-customer list. | Medium | SU010, SU001 |
| CU021 | The 2026 strategy refinement sharpened the customer story toward enabling health systems to scale care-at-home programs, which reinforces B2B concentration around institutional buyers. | High | SU010, SU024 |
| CU022 | Public underwriting is missing active program counts, patient repeat-use cohorts, account expansion rates, and renewal dates. | Low | SU010, SU022 |
| CU023 | A careful proxy cohort view would treat patient repeat usage as lower than enterprise-partner retention, because many acute episodes are episodic while institutional relationships can persist for years. | Medium | SU006, SU003, SU004 |
| CU024 | The 2025 scale-backs raise a customer-quality question: some markets or service lines may not have reached the density needed to support durable service consistency. | Medium | SU015, SU001 |
| CU025 | Nonetheless, the named partner list and 50+ enterprise-customer disclosure together support a credible customer proof file for a private healthcare startup. | High | SU001, SU003, SU004, SU013 |
| CU026 | The biggest customer weakness is not lack of proof but lack of retention and concentration transparency. | Medium | SU010, SU022, SU019 |
| CU027 | Locations and patient-access materials keep the patient journey simple, but they do not change the fact that most economic leverage sits in enterprise channels. | High | SU025, SU008, SU007 |
| CU028 | The company's public site still presents a direct patient request path, which likely helps lead generation and payer routing even inside a B2B-heavy model. | Medium | SU008, SU025 |
| CU029 | Named partner proof spans both payer and provider channels, which is stronger than having only one side of the market represented. | Medium | SU003, SU004, SU014 |
| CU030 | Consumer review evidence is noisier and lower quality than enterprise proof, so customer diligence should weight partner references more heavily than generic review sites. | Medium | SU016, SU018, SU003 |
| CU031 | The company likely has limited classic self-serve multi-homing because care is delivered through covered episodes and provider workflows rather than casual app sessions. | High | SU007, SU008, SU010 |
| CU032 | StartupIntros and Tracxn are useful only as profile surfaces and do not solve the core gaps on customer concentration or retention. | Medium | SU019, SU022 |
| CU033 | Regence and Valley workflow pages both imply a bundled customer experience that includes clinical visit, billing, and coordination, reinforcing the service depth of the offering. | Medium | SU014, SU027 |
| CU034 | The Saint Francis launch demonstrates that customer acquisition can continue even after post-merger rationalization, which helps rebut a purely retrenching narrative. | Medium | SU013, SU012, SU015 |
| CU035 | Public customer proof is strongest on named accounts and cumulative patients treated, and weakest on renewal math and account-level economics. | Medium | SU001, SU006, SU019 |
| CU036 | Overall, DispatchHealth appears to have real enterprise customer traction and credible reference quality, but investors still need retention and concentration data before assuming durable expansion economics. | High | SU001, SU010, SU003, SU004 |
| CR001 | The single biggest DispatchHealth risk is execution risk inside a capital- and labor-intensive care-at-home operating model. | High | SR001, SR008, SR009 |
| CR002 | The 2030 extension of AHCAH materially reduced near-term federal policy cliff risk for hospital-at-home programs. | High | SR015, SR014 |
| CR003 | Policy risk remains meaningful because DispatchHealth's business still spans reimbursement structures and state-by-state realities beyond one federal waiver. | High | SR017, SR007, SR029 |
| CR004 | CHCS reported that only 12 state Medicaid agencies reimbursed hospital-at-home in fee-for-service Medicaid as of 2025, limiting universality of the model. | Medium | SR017 |
| CR005 | No major public litigation or enforcement file was surfaced in this run, but the absence of visible disputes is not the same as a clean legal diligence file. | Medium | SR010, SR007 |
| CR006 | Operational risk is elevated because the model requires staffing, scheduling, logistics, diagnostics, and escalation reliability in each local market. | High | SR008, SR009, SR018 |
| CR007 | Quality risk cannot be ignored even with positive company metrics because high-acuity care in the home can fail through delayed escalation, staffing mismatches, or coordination gaps. | High | SR018, SR019 |
| CR008 | The 2025 market scale-back and layoffs are concrete evidence that some markets or service lines did not justify the existing footprint after the merger. | Medium | SR001, SR013 |
| CR009 | Archived Glassdoor and broken Indeed / Trustpilot review paths suggest non-trivial people and reputational risk, even if the signal quality is imperfect. | Medium | SR002, SR036, SR035 |
| CR010 | Headcount ambiguity across alternative-data sources makes it harder to judge post-merger org stability and productivity. | Medium | SR027, SR028, SR031 |
| CR011 | Partner dependence is structurally important because payers, health systems, and channel partners control referrals, coverage, and operating context. | High | SR011, SR012, SR007 |
| CR012 | Public sources do not disclose top-customer exposure, so concentration risk is plausible but unmeasured. | Low | SR013, SR026 |
| CR013 | Technology and data risk are hard to underwrite because public materials discuss EMR integration and orchestration but not formal security certifications, SLAs, or uptime history. | Medium | SR009, SR010 |
| CR014 | Financial-model risk is high because investors cannot reconcile revenue, margin, burn, debt, and valuation from accessible public sources. | Low | SR025, SR022, SR024 |
| CR015 | Valuation opacity is itself a risk because alternative-data pages point to marks that the accessible open record does not corroborate cleanly. | Medium | SR022, SR023, SR024 |
| CR016 | The leaked-doc reporting around Medically Home suggests merger integration risk and raises the possibility that DispatchHealth inherited pressure rather than only synergy. | Medium | SR021, SR013 |
| CR017 | Competitor and adjacency risk remains meaningful because health systems can build internally and point solutions can attack single workflow layers. | Medium | SR040, SR039, SR031 |
| CR018 | Public mitigations include ACHC accreditation, repeated outcomes claims, and a refined strategy that narrows focus toward scalable health-system enablement. | High | SR006, SR019, SR007 |
| CR019 | Key monitoring indicators should include market exits, layoffs, payer-coverage breadth, named-launch cadence, and whether new customers continue to go live after the merger. | Medium | SR001, SR041, SR015 |
| CR020 | A credible thesis-break trigger would be renewed footprint contraction or evidence that partner demand is insufficient to support dense local operations. | Medium | SR001, SR007 |
| CR021 | Another thesis-break trigger would be proof that economics rely on unsupported valuation assumptions rather than on visible margin improvement and partner expansion. | Medium | SR025, SR024, SR007 |
| CR022 | Consumer-trust risk exists but appears secondary to enterprise-partner trust, because customer proof is driven more by hospital and payer references than by review sites. | Medium | SR003, SR005, SR011 |
| CR023 | The presence of broken review endpoints and complaint surfaces is worth preserving as noise in the trust file even if it is not thesis-breaking on its own. | Medium | SR037, SR038, SR004 |
| CR024 | Headcount ambiguity also creates succession and change-management risk because the post-merger operating base may be much larger or more volatile than alternative-data summaries imply. | Medium | SR027, SR028, SR001 |
| CR025 | Category instability is visible in Current Health changing hands, Contessa's inactive public presence, and post-merger adjustments at DispatchHealth itself. | Medium | SR033, SR034, SR001 |
| CR026 | The open risk file still lacks verified churn, margin, litigation, incident, and service-level data. | Low | SR007, SR009, SR026 |
| CR027 | Overall risk is elevated but not fatal: the company has real mitigants and proof points, yet the investment case still depends on dense execution and better private disclosure. | High | SR007, SR006, SR001, SR013 |
| CR028 | Regulatory risk has shifted from existential federal-waiver risk toward uneven monetization and state/payment complexity. | High | SR015, SR017, SR014 |
| CR029 | Operational quality risk is partially mitigated by published outcomes and accreditation, but those do not remove the need for local staffing density and escalation discipline. | High | SR006, SR019, SR018 |
| CR030 | The imaging-business divestiture shows management is willing to reshape assets, which can be a mitigation if it improves focus but a risk if it signals portfolio stress. | Medium | SR020, SR007 |
| CR031 | Partner dependency risk extends beyond customers to reimbursement and channel logic, which means policy and commercial risks can reinforce each other. | High | SR012, SR017, SR029 |
| CR032 | Public employee-sentiment sources are too noisy to stand alone, but they reinforce the broader execution-risk story created by layoffs and restructuring. | Medium | SR002, SR001, SR036 |
| CR033 | The BBB pages themselves are disclaimer heavy, which limits how much weight can be put on complaint counts alone. | Medium | SR003, SR004 |
| CR034 | The refined 2026 strategy is a mitigation only if it leads to more disciplined market selection and better customer density. | Medium | SR007, SR001 |
| CR035 | A cautious investor should demand operating dashboards and contract-level economics before underwriting the post-merger risk profile as stable. | Medium | SR013, SR026, SR025 |
| CR036 | Because this is healthcare delivery rather than pure software, small operational mistakes can have outsized brand, quality, and reimbursement consequences. | High | SR008, SR018 |
| CR037 | The company's strongest risk mitigant is that it still shows active launches and strategic focus despite retrenchment, which argues against immediate thesis collapse. | High | SR041, SR007, SR013 |
| CR038 | DispatchHealth publishes a privacy policy, terms of service, HIPAA notice, employee privacy notice, state privacy-rights page, and non-discrimination statement, which creates a visible legal-compliance surface. | Medium | SR042, SR043, SR044, SR045, SR046, SR047 |
| CR039 | Those legal disclosures mitigate basic transparency concerns, but they do not substitute for incident history, security attestations, or regulatory-audit evidence. | Medium | SR042, SR043, SR044 |
| CR040 | The HIPAA notice reinforces that DispatchHealth operates inside sensitive PHI workflows, which raises the severity of any security or operational failure. | Medium | SR044, SR009 |
| CV001 | DispatchHealth closed the Medically Home merger in June 2025 and said the combined platform had more than 50 enterprise customers, treated more than 1.2 million people, and operated across more than 20 states. | High | SV001, SV006, SV008 |
| CV002 | The company’s July 2026 strategy update reframed DispatchHealth around enabling health systems to scale complex care at home rather than only around direct house calls. | High | SV003, SV004 |
| CV003 | PitchBook lists a completed Later Stage VC (Series E1) financing on 12-Mar-2025 and another completed Later Stage VC financing on 30-Apr-2026. | Medium | SV028 |
| CV004 | Forge reported that a 12-Mar-2025 Series E-1 round raised $106.88 million at a $3.58 billion post-money valuation. | Medium | SV013, SV028 |
| CV005 | Forge also reported that a 30-Apr-2026 Series A-1 financing raised $97.71 million at a $703.5 million post-money valuation. | Medium | SV013, SV028 |
| CV006 | The open record therefore contains a severe valuation spread between the March 2025 Forge mark and the April 2026 Forge mark. | Medium | SV013, SV028 |
| CV007 | That spread likely reflects either a sharp reset, security-specific pricing, or cap-table complexity that public sources do not explain well enough. | Medium | SV013, SV011, SV028 |
| CV008 | Notice surfaces an $888.31 DispatchHealth stock headline but provides too little context to use it as a standalone fair-value anchor. | Medium | SV015 |
| CV009 | Nasdaq Private Market confirms DispatchHealth remains private, has no public ticker, and is traded through secondary-market workflows rather than public exchanges. | Medium | SV014 |
| CV010 | DispatchHealth’s accessible company pages do not publish audited revenue, gross margin, EBITDA, or cash-flow statements. | High | SV001, SV004, SV003 |
| CV011 | Fierce Healthcare reported in 2020 that Optum Ventures backed a $135.8 million round, showing strategic health-system and payer-adjacent capital has been in the story for years. | Medium | SV010 |
| CV012 | Medhealth Outlook reported that DispatchHealth raised roughly $330 million of debt and equity in 2022, indicating the capital stack likely includes structured financing beyond simple common equity. | Medium | SV011 |
| CV013 | Because revenue is private, the valuation exercise has to triangulate between observed private marks, public trading comps, and strategic-scarcity arguments. | High | SV013, SV001, SV031, SV035 |
| CV014 | The best public directional comp set for this chapter trades at low revenue multiples rather than at software-style growth multiples. | Medium | SV031, SV035, SV032, SV036, SV033, SV034 |
| CV015 | Teladoc traded at about 0.48x trailing sales and 0.58x EV/sales on 20-Aug-2026, giving a distressed digital-health floor reference. | Medium | SV031 |
| CV016 | Option Care traded at about 0.62x trailing sales and 0.81x EV/sales on 20-Aug-2026, offering a useful home-based care adjacency. | Medium | SV035 |
| CV017 | CVS traded at about 0.29x sales on 20-Aug-2026. | Medium | SV032 |
| CV018 | Humana traded at about 0.31x sales on 20-Aug-2026. | Medium | SV036 |
| CV019 | UnitedHealth traded at about 0.77x sales on 20-Aug-2026. | Medium | SV033 |
| CV020 | Best Buy traded at about 0.44x sales on 20-Aug-2026, reminding investors that home-health adjacency by itself does not guarantee premium public multiples. | Medium | SV034, SV037 |
| CV021 | Teladoc and CVS both publish audited annual reports with complete public financial statements, while DispatchHealth does not. | High | SV029, SV030, SV001 |
| CV022 | The comp set is therefore helpful for direction but insufficient for precision because the revenue denominator for DispatchHealth is still not public. | High | SV031, SV035, SV001, SV012 |
| CV023 | A strategic premium is still arguable because DispatchHealth owns a scaled, national in-home acute-care footprint that large payers or health systems could find difficult to rebuild quickly. | Medium | SV001, SV005, SV003 |
| CV024 | A strategic premium is not automatically deserved because DispatchHealth is an operationally heavy care-delivery business, not a pure software platform. | High | SV004, SV035, SV032 |
| CV025 | Competitor churn reinforces price discipline: Best Buy exited Current Health, while Contessa’s standalone site is inactive. | High | SV018, SV019, SV023 |
| CV026 | The leaked-doc reporting around Medically Home and DispatchHealth’s own post-merger scale-back also weaken the case for simply paying the prior headline mark. | Medium | SV016, SV017 |
| CV027 | A bear case from open evidence is a reset range near roughly $0.6-1.0 billion, anchored by the 2026 Forge mark and low public healthcare multiples. | Medium | SV013, SV031, SV035, SV032 |
| CV028 | A base case from open evidence is roughly $1.5-2.4 billion, which still grants a meaningful premium to low public multiples but discounts the March 2025 Forge mark for opacity and execution risk. | Medium | SV013, SV001, SV035, SV033 |
| CV029 | A bull case from open evidence is roughly $3.0-3.8 billion and only works if management can prove strong 2025-2026 growth, payer density, and clean cap-table mechanics. | Medium | SV013, SV001, SV036, SV033 |
| CV030 | The March 2025 Forge mark is best treated as a ceiling reference, not as today’s default fair value. | Medium | SV013, SV017, SV016 |
| CV031 | The April 2026 Forge mark may be security-specific rather than whole-company fair value, but it is too material a datapoint to ignore in negotiation. | Medium | SV013, SV028 |
| CV032 | A near-term IPO looks less plausible than strategic M&A or structured private financing because DispatchHealth is still routed through private-market venues and publishes no public-company filing trail. | Medium | SV014, SV028 |
| CV033 | Potential strategic buyer logic exists for health plans, provider platforms, or retail-health hybrids that want a scaled in-home acute-care capability. | Medium | SV020, SV022, SV003 |
| CV034 | The most important diligence gates are audited 2025 revenue, cap-table terms for the 2025 and 2026 financings, and market-level cohort economics. | High | SV013, SV028, SV001 |
| CV035 | If those gates come back strong, downside narrows because the company’s scale, strategic backers, and category position are all real. | Medium | SV001, SV010, SV005 |
| CV036 | If those gates come back weak, the open record already provides enough warning signs to justify a hard pass above the low-single-digit billions. | Medium | SV013, SV017, SV016, SV018 |
| CV037 | Even though hospital-at-home market reports describe growth, value capture can still accrue to payers and health systems rather than to the standalone operator. | Medium | SV024, SV025, SV036, SV033 |
| CV038 | Open-web price discovery confirms relevance, but it does not confirm a single trustworthy fair-value number. | Medium | SV013, SV015, SV014, SV028 |
| CV039 | Small changes in assumed multiple or hidden revenue denominator can move the implied value by billions, which is why recommendation confidence should remain only medium. | Medium | SV013, SV031, SV033 |
| CV040 | The safest final recommendation is conditional only: do not underwrite a purchase at or above the March 2025 Forge mark without audited operating data and explicit reconciliation of the 2026 financing terms. | High | SV013, SV029, SV030, SV028 |